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LIST OF ABBREVIATIONS  
 
AD Alzheimer`s disease 
APP Amyloid Precursor Protein 
Aβ β-amyloid peptide 
CD Cluster of Differentiation 
CGD  Chronic Granulomatous Disease  
CNS Central Nervous System 
CR Complement receptor 
DPI Diphenyleneiodonium chloride 
DMSO Dimethyl Sulfoxide 
FAD Flavin Adenine Dinucleotide  
FAD Familial AD 
FPR Formyl Peptide Receptor 
fMLP N-Formyl-L-Methionyl-L-Leucyl-L-Phenylalanine 
GFP Green Fluorescent Protein 
IL Interleukin 
KPI Kunitz class of serine-Protease Inhibitor 
LBP LPS-Binding Protein 
LPS Lipopolysaccharide 
MAC Membrane Attack Complex 
MCP Monocyte Chemoattractant Protein 
MHC Major Histocompatibility Complex 
MIP Macrophage Inflammatory Protein 
M-CSF Macrophage Colony-Stimulating Factor 
MW Molecular Weight 
NADPH Nicotinamide Adenine Dinucleotide Phosphate  
NBT Nitro Blue Tetrazolium 
NFT Neurofibrillary Tangle 
Nox NADPH oxidase 
NMDA N-Methyl-D-Aspartate 
Phox Phagocyte oxidase 
RAGE Receptor for Advanced Glycation Endproduct 
ROS Reactive Oxygen Species 
SOD Superoxide Dismutase  
SP Senile Plaque 
TGF-β Transforming Growth Factor-β 
TNF-α Tumor Necrosis Factor-α 
wt Wild type 
3m Triple mutants 
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RESUME ET INTRODUCTION 
 
  La Démence d’Alzheimer (DA) est une de pathologies neuro-dégénérative les plus 
fréquente chez le sujet âgé. Elle serait responsable de plus de 50-70% des cas de démence 
diagnostiqués dans le monde. Cependant l’étiopathogénie de cette maladie n’est que 
partiellement connue. Les principales caractéristiques histopathologiques sont les plaques 
séniles extracellulaires et la dégénérescence neurofibrillaire associées à une importante 
perte neuronale, une gliose, une angiopathie amyloïde et une dégénérescence vasculaire 
Les plaques séniles sont classiquement représentées par le dépôt de fibrilles de peptides 
β-amyloïde (Aβ) et de fragments dérivés de la protéolyse de la protéine précurseur d’Aβ 
appelée APP (Braak and Braak, 1991; Braak et al., 1998; Butterfield et al., 2002; Dickson 
et al., 1992; Nagy et al., 1998).  
  L’APP est un ensemble de protéines transmembranaires composées de 695 à 770 
résidus, codées par un mRNA ayant présenté des transcriptions alternatives d’un même 
gène situé sur le chromosome 21 (Glenner and Wong, 1984). Un ensemble d’enzymes 
protéolytiques appelées α, β ou γ-secretases peuvent lyser l’APP. Le clivage de l’APP 
donne naissance à des peptides Aβ d'une longueur de 40- to 43-résidus. Aβ 42 a une 
tendance particulière à former des fibrilles Aβ jusqu’à réaliser les plaques typiques 
retrouvées dans le cerveau des patients atteints de DA. Le dépôt d’Aβ 42 accélère 
l’accumulation Aβ 40 et stimule une cascade de réaction conduisant à la formation de 
plaques sénile et de plaques neurofibrillaires aboutissant à la mort neuronale (Gandy and 
Greengard, 1994; Selkoe, 2001). 
  Bien que seulement 1% des DA familiales sont des pathologies héréditaires sur le mode 
autosomal dominant, ces cas sont importants pour la compréhension des mécanismes 
conduisant aux dépôts de substances Aβ retrouvés dans tous les cas de DA. La DA 
familiale la plus commune est liée à la mutation british, dans laquelle une valine 
remplace une isoleucine au sein du domaine transmembranaire (V717I) (Goate et al., 
1991). Une autre forme familiale de DA est représentée par la double mutation suédoise 
dans laquelle il existe une mutation tandem à la partie N terminale du domaine Aβ (Lys 
(K)—Met (M), Asn (N)—Leu (L); 670 KM/671 NL) (Mullan et al., 1992). La majorité 
de ces mutations affecte l’activité des secrétases aboutissant à une surproduction du 
peptide toxique et amyloido-formateur Aβ 42.  
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  De nouvelles recherches dans le domaine fondamental ou clinique permettent 
continuellement d’améliorer nos connaissances sur la DA. Dans ce sens, l’inflammation 
chronique a été récemment impliquée dans la pathogénie de la DA; il apparaît clairement 
qu’elle existe dans certaines parties atteintes par la DA (Aisen and Davis, 1994; Akiyama 
et al., 2000; Bamberger and Landreth, 2002; Tuppo and Arias, 2005). On retrouve 
communément de la microglie activée autour des protéines Aβ des cerveaux atteints. La 
microglie a des capacités à produire des substances pro-inflammatoires et neurotoxiques 
variables incluant:1) des produits radicalaires appelés Espèces Réactives de l’Oxygène 
(EOR) (El Khoury et al., 1996; Giulian et al., 1994); 2) des cytokines de différentes 
superfamilles telles que les interleukines (ILs), tumor necerois factor-α (TNF-α), 
transforming growth factor-β (TGF-β), monocytes chemoattractants protein-1 (MCP-1), 
macrophage inflammatory protein-1α (MIP-1α) et des chémokines (Giulian et al., 1994); 
3) des protéines complémentaires ; 4) des acides aminés excitatoires; 5) des métabolites 
d’acides gras et 6) des enzymes protéolytiques (Akiyama et al., 2000; Bamberger and 
Landreth, 2002). Ceci suggère assez nettement que la notion d’inflammation induite par 
la microglie participe à la pathogénie de la DA ou à l’apoptose (Aisen and Davis, 1994; 
Akiyama et al., 2000; Bamberger and Landreth, 2002; Streit, 2004; Tuppo and Arias, 
2005).  
  Une des caractéristiques la plus constante de la microglie activée consiste en une grande 
production radicalaire soit, de radical hydroxyle (OH ), peroxyde d’hydrogène (H2O2) et 
anions superoxydes (O2−). Les ERO sont produits par l’activation d’enzyme membranaire 
la nicotinamide adénine dinucléotide phosphate (NADPH) oxydase qui est responsable 
du burst respiratoire (McGeer and McGeer, 2003; Rogers and Lue, 2001).  
  Plusieurs études ont montrés que le stress oxydant est une élément majeur de la 
pathogénie de la DA (Good et al., 1996; Mark et al., 1996). Le concept de stress oxydant 
fait référence au dépassement des capacités anti-oxydantes endogènes face à la 
production oxydante qui conduit à des dégâts moléculaires et tissulaires. Un tel état peut 
être lié à une surproduction de radicaux libres ou/et à une diminution des capacités anti-
oxydantes incluant les molécules naturelles suivantes, glutathione, vitamine E, ascorbate, 
le système glutathione peroxydase, superoxyde dismutase (SOD) et catalase. Les SOD 
sont des metalloenzymes qui catalysent la dismutation des anions superoxydes (O2−) en 
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H2O2 et une molécule d’O2. La Catalase est une autre enzyme importante qui permet de 
neutraliser l’effet toxique d’H2O2 tandis que la glutathione peroxydase permet à la fois de 
neutraliser l’effet toxique d’H2O2 et transforme les résidus hydroperoxydes des lipides en 
alcool non toxique. Dans la DA, la surproduction de ERO serait des signaux médiateurs à 
l’origine des dégâts cellulaires  et de l’apoptose.  
  L’origine exacte du stress oxydant n’est pas définitivement établie et de multiples 
cascades biochimiques semblent impliquées: a) les ERO tels que OH , H2O2 et O2− 
peuvent être surproduits par l’activation des cellules de la microglie à travers le « burst 
respiratoire » (Akiyama et al., 2000; McGeer and McGeer, 2003; Rogers and Lue, 2001). 
b) l’Aβ peut initier une cytotoxicité direct sur les neurons aboutissant à la production de 
ERO (Mattson, 1997) c) l’Aβ peut aussi produire des radicaux libres directement ou 
indirectement dans les neurons en interagissant avec, des produits de glycations tels que 
les RAGE (Yan et al., 1996), le CR3, le CD14 et le N-formyl peptide receptors (FPRs) 
(Chang et al., 1993; Fassbender et al., 2004; Tsuruki et al., 2003). Bien que les récepteurs 
macrophagiques sont impliqués dans la phagocytose Durant le processus inflammatoire, 
les mécanismes précis de l’activation de la microglie associés à l’Aβ  sont encore peu 
élucidés.  
  Récemment plusieurs études ont mis l’accent sur le rôle potentiel des ERO comme 
régulateurs de l’apoptose; Une source importante de ERO commune à toute les cellules , 
globules rouges exceptés, est le système de transport électronique mitochondrial (Babior, 
1999; Quillet-Mary et al., 1997; Wang et al., 1996). Par contre, dans les cellules 
phagocytaires la plus importante est celle générée par les NADPH oxydase, autrement 
appelé « burst respiratoire ». Il catalyse le transfert électronique du substrat NADPH à l’ 
O2 par un intermédiaire flavin adenine dinucleotide (FAD) et un hème, pour produire 
l’anion superoxyde, O2 , il va lui même conduire à la formation d’autres espèces 
radicalaires tels que OH  et H O . 2 2
  Les recherches concernant les mécanismes impliqués dans la mort cellulaire de la DA 
ont permis de mieux comprendre comment l’apoptose et la néceroe contribuent à la 
neurodégénérescence (Kusiak et al., 1996; Wolozin and Behl, 2000). L’apoptose se réfère 
à une forme de mort cellulaire programmée dont les caractéristiques morphologiques sont 
sous la dépendance d’évènements cellulaires impliquant l’activation des caspases; leurs 
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activation tue les cellules. Les caspases représentent une famille de protéases cysteinées 
parmi lesquelles existent des proenzymes devant être clivées pour être actives; ce clivage 
leur confère le pouvoir d’initier une cascade d’évènements cellulaires qui prennent des 
caractéristiques apoptotiques telles que le clivage ADN, la densification nucléaire et le 
bourgeonnement de la membrane cytoplasmique. Malgré ces évidences certains auteurs 
étudiant la toxicité Aβ  sont plus en faveur de mécanisme de nécrose que de mécanismes 
liés à une apoptose caspase dépendante. LA mort cellulaire nécrotique est caractérisée par 
la liquéfaction cellulaire suivi par la rupture membranaire et le largage du matériel 
intracytoplasmique dans l’espace intercellulaire. Le tissus nécrotique peut être épurée par 
des réactions cellulaires inflammatoires. Il apparaît donc qu’apoptose et nécrose sont 
ensemble en cause dans la mort cellulaire neuronale de la DA. 
  La microglie, qui est issue d’un groupe de cellules en lien avec les monocytes et 
macrophages circulant peut dans un sens représenter les macrophages du système 
nerveux central (SNC). Ils sont particulièrement sensibles aux modifications 
environnementales incluant la présence de bactéries, virus, protéines étrangères, débris 
cellulaires et composants cellulaires anormaux (Akiyama et al., 2000; Bamberger and 
Landreth, 2002).  
  La microglie à l’état inactif est composée de cellules ramifiées et présente à l’état 
normal dans le cerveau; elle peut cependant être activée par une large série de stimuli lors 
d’une souffrance cérébrale. Les effets de la microglie sur les neurones dépendent du stade 
d’activation de cette microglie (Kreutzberg, 1996). Le mécanisme précis de l’atteinte 
neuronale dû à l’activation de la microglie n’est que partiellement élucidé. Plusieurs 
études ont impliqué 1) des neurotoxines agissant de manière indirecte; In vitro, la 
microglie peut être activée par les lipopolysaccharides (LPS), (endotoxine de la 
membrane bactérienne), (Bronstein et al., 1995). Il est maintenant généralement admis 
que la microglie activée contribue au processus de neurodégénérescence à travers la 
sécrétion de médiateurs pro-inflammatoires et de facteurs neurotoxiques qui accentuent la 
dégénérescence neuronale (Akiyama et al., 2000; Bamberger and Landreth, 2002; 
McGeer and McGeer, 2003). 2) des neurotoxines agissant de manière directes; les deux 
neurotoxines expérimentales suivantes, la 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) et l’hydroxydopamine (6-OHDA) sont de bons exemples de toxicité directe sur 
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les neurones dopaminergiques. L’atteinte directe des neurones par ces agents cause une 
gliose réactionnelle (Cicchetti et al., 2002; Wu et al., 2002). 3) un mode mixte des 
mécanismes de neurotoxicité. Ceci inclus l’Aβ, la gp120, les peptides dérivés de la 
protéine prion, et le pesticide roténone. L’augmentation de la neurotoxicité de l’Aβ (1-
42) a été attribuée en premier à l’activation microgliale et aux conséquence de la présence 
de radicaux superoxydes. 
  L’objectif principal de ce travail de thèse était d’établir un modèle cellulaire simple des 
composants de l’inflammation neuronale retrouvée dans la maladie d’Alzheimer. Nous 
avons postulé que la co-culture de microglie et de cellules neuronales exprimant l’APP 
pouvait nous permettre d’obtenir ce modèle. Cependant les objectifs associés étaient de 
mieux comprendre les mécanismes régissant l’inflammation neuronale et en particulier 
l’activation microgliale associée à la neurodégénérescence de la DA mais aussi d’utiliser 
ce modèle pour de nouvelles approches thérapeutiques. Dans ce modèle il devrait être 
possible de définir et développer des approches thérapeutiques visant l’activité des anti-
inflammatoires, des agents neuro-protecteurs, tels que les antioxydants, les antiTNF-α, 
les hypolipémiants, les inhibiteurs de la phosphodiestérases et certaines plantes 
médicinales chinoises. Nous émettons l’hypothèse que l’inhibition de la production 
d’ERO peut être une approche thérapeutique très efficace comparées aux stratégies 
conventionnelles qui n’inhibe la production que de certains facteurs cytotoxiques,. De la 
même manière, des agents actifs sur les récepteurs impliqués dans l’interaction fibrilles 
amyloïdes et microglie ou macrophages devraient avoir le même potentiel thérapeutique. 
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ABSTRACT  
 
  Reactive oxygen species (ROS) are thought to play a role in the neuroinflammatory 
component of Alzheimer’s disease (AD). Yet, the source of ROS in this context remains 
unclear. We have generated through lentiviral transduction APP expressing SH-SY5Y 
neuroblastoma cells that over express wild-type or mutant APP (amyloid precursor 
protein). Over expression of APP did not alter morphology, growth, or sensitivity to 
hydrogen peroxide of SY-SH5Y cells. However, upon co-culture with microglia, APP-
expressing, but not control SH-SY5Y cells died. SH-SY5Y cells-expressing APP with 
mutations typical for familial AD (APP-3m), were more severely affected than those 
expressing wild type APP (APP-wt). Upon co-culture with APP-expressing cells, but not 
with control SH-SY5Y cells, microglial cells generated ROS. Death of APP-expressing 
SH-SY5Y cells was largely prevented by ROS-scavengers, demonstrating a role of ROS 
in our cellular model. The NADPH oxidase inhibitor DPI dose-dependent prevented 
neuronal death in the co-culture system at a concentration range between 0.05 and 1 µM 
(higher DPI concentrations were neurotoxic). Macrophage cell lines had a similar effect 
as those of the microglia in the co-culture model. However, a macrophage cell line 
deficient in the gp91phox subunit of the phagocyte NADPH oxidase had a strongly 
diminished capacity of neuronal killing in the co-culture system. These results suggest 
that APP-dependent microglia activation and subsequent ROS generation by the 
phagocyte NADPH oxidase play a crucial role in inflammatory neuronal killing in a 
cellular model of AD. 
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INTRODUCTION 
 
1. Alzheimer’s disease 
  Alzheimer’s disease (AD) was first described by Alois Alzheimer in 1907 (Bamberger 
and Landreth, 2002). It is currently one of the most common neuro-degenerative diseases 
of aging, accounting for more than 50% of dementia cases worldwide, with an increasing 
prevalence in the aged population. The aetiology and pathogenesis of AD are still not 
completely known, but a number of factors may be associated with the onset of the 
disease. Individuals with an extra copy of chromosome 21 (Down syndrome), with 
mutations in the presenilin genes on chromosome 1 and 14 or with mutations in the 
amyloid precursor protein (APP) gene on chromosome 21 are at a great risk of 
developing AD. Most cases (i.e. >95%) of Alzheimer's disease however do not have 
defined genetic mutations, but occur "sporadically" in the elderly. A well known risk 
factor (but not causative mutation) in the sporadic form of AD is the ε 4 allele of the 
apolipoprotein E gene on chromosome 19.  
                                                                  
Fig. 1. The extracellular senile plaque (SP) and intraneuronal neurofibrillary tangle 
            (NFT) 
  Several characteristic pathological changes have been observed, which are believed to 
originate in the cerebral cortex namely in the temporal and parietal lobes and then 
selectively spread to the subcortical regions, predominantly the hippocampus and 
amygdala. The defining features of the pathology in AD are cortical atrophy in the form 
of gyral shrinkage, widening of the sulci and enlargement of the ventricles. The typical 
microscopic hallmarks are the presence of extra cellular senile plaques (SP) and 
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intraneuronal neurofibrillary tangles (NFT) (Fig. 1) accompanied by profound synaptic 
and neuronal loss, marked gliosis, amyloid angiopathy and granulovascular degeneration. 
The classical SPs are generated by a deposition of fibrils of the β-amyloid peptide (Aβ) 
in the human brain, with its fragments derived from the proteolytic processing of APP. 
The NFTs are a compact filamentous network formed by paired helical filaments (PHF) 
composed of abnormal phosphorylated tau protein (Braak and Braak, 1991; Braak et al., 
1998; Butterfield et al., 2002; Dickson et al., 1992; Nagy et al., 1998).  
  AD is characterized clinically by an insidious onset. Patients experience a decline in the 
ability to accomplish routine activities of daily living, demonstrate enduring changes in 
personality and behavior, show marked memory loss by manifestation of poor recall of 
recent information and preservation of remote memories, and eventually undergo 
progressive and global dementia. Among associated symptoms of AD is a decline in 
language function, initially observed as a loss of fluency but eventually leading to 
aphasia, visual-spatial impairment, impaired ability in calculation and abstraction, and 
disturbances of other cortical functions such as agnosia and apraxia. Important behavioral 
changes, including delusions, insomnia, depression, agitation, and wandering are 
frequently observed and contribute to the severity of the clinical disease (Nagy et al., 
1998; Prayson and Estes, 1994). 
  Treating AD is a major challenge in clinical practice. The practical therapeutic 
approaches include cholinesterase inhibitors, blockers of the N-methyl-D-aspartate 
(NMDA) receptor, antioxidants or blockers of oxidative deamination (including Gingko 
biloba), anti-inflammatory agents, neurotrophic factors (including hormone replacement 
therapy and drugs acting on insulin signal transduction) and antiamyloid agents 
(including cholesterol-lowering therapy). In fact, however, none of the above mentioned 
approaches has been proven to be promising and hence there is no effective drug to cure 
AD.  
  New research data and clinical experiences continuously broaden our knowledge of AD. 
Chronic inflammation has been implicated in the pathogenesis of AD and clearly occurs 
in vulnerable regions of the AD brain (Aisen and Davis, 1994; Akiyama et al., 2000; 
Bamberger and Landreth, 2002; Tuppo and Arias, 2005). How and when the chronic 
inflammation arises in the course of AD has not yet been fully resolved, and what, if any, 
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pathophysiologic significance the neuro-inflammation has in the development of the 
dementia itself still remains unknown.  
1.1 Alzheimer’s disease and Inflammation  
  In the AD brain, damaged neurons, neurites, highly insoluble amyloid plaques and 
neurofibrillary tangles provide obvious potential stimuli for inflammation. Inflammatory 
mediators have been observed in the AD brain over the last 15 years, and more recent 
reports confirm and extend our knowledge of the inflammatory molecules in AD brain 
and indicate that the inflammation may exacerbate neuronal degeneration. However, AD 
inflammatory research has often been categorized in groups specializing in cytokines 
(chemokines), reactive oxygen species (ROS), complements, various proteolytic 
enzymes, and so on (Aisen and Davis, 1994; Akiyama et al., 2000; Bamberger and 
Landreth, 2002; Streit, 2004; Tuppo and Arias, 2005).  
  The presence of a large number of activated microglia was originally observed during 
the postmortem analysis of the brains of AD patients. Reactive microglia around the Aβ 
is a common pathologic finding in AD-affected brains, however, the microglia and 
reactive astrocytes in brain tissue were originally interpreted as a secondary inflammatory 
response, and not as a causative factor. The secondary role of these cells has become 
subject to controversy. The ability of microglia to produce and release a variety of 
neurotoxic pro-inflammatory mediators including tumor necrosis factor-α (TNF-α), 
interleukin-1 (IL-1), proteases and ROS suggests that microglia may contribute to the 
neuro-degenerative process (Aisen and Davis, 1994; Akiyama et al., 2000; Bamberger 
and Landreth, 2002; Streit, 2004; Tuppo and Arias, 2005).  
  One of the most invariant features of activated microglia is the production of large 
amounts of ROS, i.e. hydroxyl radicals (OH ), hydrogen peroxide (H2O2) and superoxide 
anion (O2−). ROS is produced following the activation of membrane bound nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase, which is associated with the 
respiratory burst and the expression of inducible nitric oxide synthase (iNOS) (McGeer 
and McGeer, 2003; Rogers and Lue, 2001). Once produced, ROS may, for example, 
induce the release of glutamate from neurons, which can stimulate NMDA receptors and 
trigger excitoxicity. The presence of reactive microglia co-localized with amyloid 
plaques in the cortical region of AD brains, the detection of elevated levels of pro-
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inflammatory mediators and the evidence of oxidative stress-mediated damage in 
postmortem AD brains have lent strong support to the notion that microglia-induced 
inflammation is involved in the pathogenesis of AD (Dickson et al., 1993; Rogers et al., 
2002; Streit, 2004).  
1.2 Alzheimer’s disease and Oxidation 
  Several studies have implicated oxidative stress as a major pathogenic mechanism in 
AD (Good et al., 1996; Mark et al., 1996). The concept of oxidative stress refers to a state 
in which oxidant production surpasses the endogenous antioxidant capacity leading to 
oxidative molecular damage of the tissue. Such a state can be achieved either by 
increased production of cellular oxidants and/or decreased cellular antioxidant capacity 
including glutathione, vitamin E, ascorbate, the glutathione peroxidase system, 
superoxide dismutase (SOD) and catalase. SOD are metalloenzymes that catalyze the 
dismutation of superoxide (O2−) to H2O2 and molecular O2. Catalase is another important 
antioxidant enzyme which detoxifies H2O2 and glutathione peroxidase both detoxifies 
H2O2 and coverts lipid hydroperoxides to nontoxic alcohol. In AD an overproduction of 
ROS is considered to mediate cellular damage and signal apoptosis. 
  The exact source of the oxidative stress is unclear and multiple biochemical pathways 
are implicated: a) ROS such as OH , H2O2 and O2− can be overproduced by the 
activation of microglial cells through the respiratory burst system, which may represent 
an important source of oxidative stress (Akiyama et al., 2000; McGeer and McGeer, 
2003; Rogers and Lue, 2001); b) Aβ can initiate direct toxicity in neurons resulting in the 
generation of ROS (Mattson, 1997), including OH , H2O2 and O2−. These may in turn, 
initiate a series of secondary reactions between radicals and other biomolecules. Free 
radicals can induce massive, potentially toxic calcium entry into neuronal cells  
(MacManus et al., 2000). Free radicals can also react with metal ions such as copper, 
zinc, or iron which are found in amyloid plaques and facilitate aggregation (Atwood et 
al., 1999). These metals can also participate in Fenton type reactions with hydrogen 
peroxide to produce a strong oxidant and cytotoxin, the hydroxyl radical. Oxidative stress 
in brain cells can also arise from iron metabolism, which may alter transduction 
mechanisms related to neuro-degeneration in neuronal cells (Smith et al., 1997). c) 
Recent studies have shown that Aβ can produce free radicals directly in neurons by 
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activating the receptors of advanced glycation end products (RAGE), a type A-scavenger 
receptor (Yan et al., 1996), or indirectly by Aβ interaction with macrophage receptors 
such as CR3, CD14 (Cluster of differentiation), and N-formyl peptide receptors (FPRs) 
(Chang et al., 1993; Fassbender et al., 2004; Tsuruki et al., 2003). Although the 
macrophage receptors are involved in phagocytosis during the inflammatory process, the 
precise mechanism of Aβ−activated microglia is still poorly understood. 
  Recently, several lines of study have proposed that ROS may play a critical role in 
regulating apoptosis. An important source of ROS common to all cells except red blood 
cells is the mitochondrial electron transport system (Babior, 1999; Quillet-Mary et al., 
1997; Wang et al., 1996). The most important system for ROS generation in phagocytic 
cells is an NADPH oxidase, also known as the respiratory burst oxidase. It catalyzes the 
transfer of electrons from the substrate NADPH to O2, via intermediate flavin adenine 
dinucleotide (FAD) and heme prosthetic groups, to produce O2 , which in turn leads to 
the production of secondary derivatives such as OH  and H2O2. The superoxide 
generated by the phagocyte NADPH oxidase forms the basic compound of ROS and the 
high concentrations of ROS that exist in the phagosome are toxic and ultimately kill the 
phagocytosed cells. These radicals are critical for oxygen-dependent antimicrobial 
defense against a wide range of intra- and extracellular pathogens (Babior, 1999; 
Chanock et al., 1994; Doussiere et al., 1996; Morel et al., 1991; Roos et al., 1996).  
  NADPH oxidase is a multi-component enzyme complex, including the cytochrome b558, 
a membrane-bound flavohemoprotein comprised of two subunits, gp91phox (a large 
flavocytochrome--β sub-unit or Nox 2) and p22phox ( a small protein--α sub-unit), three 
cytosolic proteins, p47phox (phox: phagocyte oxidase), p67phox , p40phox and the small 
GTP-binding proteins, Rac1 or Rac2. Flavocytochrome b558 contains FAD and two heme 
groups needed to transfer electrons from NADPH to oxygen (Babior, 1999). The activity 
of flavocytochrome b558 is regulated by the interaction with three cytosolic proteins, 
p47phox, p67phox and Rac2 (Babior, 2002). In resting cells, cytosolic and membrane-bound 
components of the NADPH oxidase complex are dissociated. During the activation of 
phagocytotic cells by activators, such as the C5a complement fragment, cytokines, 
chemotactic peptides, opsonized bacteria or fungi, the NADPH oxidase complex becomes 
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assembled and the activated enzyme can produce bactericidal O2  (Babior, 1999; el 
Benna et al., 1994; Quinn et al., 1993).  
  Since ROS is potentially harmful to the host itself, the activity of the phagocyte NADPH 
oxidase is tightly regulated in space and time. Mutations in any of these five subunits 
(p22phox , gp91phox , p47phox, p67phox and Rac2 or p40phox ) can lead to a severe 
immunodeficiency, called chronic granulomatous disease (CGD) (Roos et al., 1996). 
CGD is a rare inherited disorder in which phagocytes lack NADPH oxidase activity. The 
disease is characterized by defective killing of phagocytosed pathogens, which leads to 
recurrent life-threatening infections. Mutations in the X-linked gene for gp91phox, the 
large subunit of the flavocytochrome b558 heterodimer, account for the majority of CGD. 
Several recent reports have suggested that the synthesis of gp91phox and its association 
with the other component of the heterodimer, p22phox, are an important step in the 
maturation of phagocytic cells (Yu et al., 1997; Zhen et al., 1993). gp91phox  is the first 
protein to be identified in a family of proteins termed Nox (1 to 5), standing for NADPH 
oxidase. gp91phox has been renamed as Nox 2. 
  A new human diploid cell line, designated PLB-985, has been established from the 
peripheral blood of a patient with acute non-lymphocytic leukemia (ANLL). Cells of this 
line are capable of granulocytic and monocytic maturation in the presence of inducing 
agents (Tucker et al., 1987). A stable human leukaemia cell line PLB-985 X-CGD has 
been generated through the disruption of gp91phox gene using a homologous 
recombination (Roos et al., 1996). PLB-985 wt and PLB-985 X-CGD, which differ only 
by the disruption of the gp91phox gene, have biphenotypic potential for differentiation into 
either neutrophils or monocytes. Thus, the two cell lines offer an excellent in vitro model 
for investigating the potential role of the NADPH oxidase in apoptosis in phagocytic 
cells.  
1.3 Alzheimer’s disease and APP 
  In the mid-1980s, Glenner and collaborators found that the amyloid deposits in the SPs 
were composed of a 4-kDa peptide with a significant beta structure called beta amyloid 
(Aβ). The Aβ peptide is derived from the proteolysis of a set of transmembrane amyloid 
precursor proteins (APP) (Glenner and Wong, 1984). APP consists of 695 to 770 
residues, encoded by alternatively spliced mRNA transcribed from a single gene on 
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chromosome 21. The ubiquitously expressed protein belongs to the type 1 transmembrane 
family of glycoproteins, called integral membrane precursor, which is involved in nuclear 
signaling processes. The N-terminal moiety of APP is projected toward the extra cellular 
domain when expressed at the cell surface, or into the lumen of intracellular vesicles, 
such as those of the endoplasmic reticulum, golgi apparatus, and intracellular endosomes 
(Neve et al., 2000). The APP C-terminal region lies in the cytoplasmic domain (Fig.2). 
The APP gene undergoes complex alternative splicing of exons, leading to heterogeneity 
in the protein (Selkoe, 2001). Further heterogeneity of APP is attained by a controlled set 
of post-translational modifications, such as N- and O-linked glycosylations, 
phosphorylations, and sulfation. 
  APP is sensitive to proteolysis by a set of proteases called, α, β or γ-secretases. 
Cleavage of APP results in the formation of 40- to 43-residue-long Aβ peptides. The α-
secretase cleaves APP inside the Aβ sequence generating peptide fragments that are not 
amyloidogenic: a soluble N-terminal part of APP (sAPPα) and a C-terminal fragment 
C83 anchored in the membrane (Fig. 2). Further γ-secretase cleavage of the C-terminal 
fragment releases a 3kD peptide p3. The β-secretase cleaves APP at the N-terminal of the 
Aβ sequence leading to 
 
Fig.2. The proteolytic processing of APP (Selkoe, 2001) 
the formation of the N-terminal part of APP (sAPPβ) and the C-terminal fragment C99. 
Subsequent cleavage of the C99 protein intermediate at the C-terminal side of the Aβ 
sequence by the γ-secretase generates the amyloidogenic form of the protein. The γ-
secretase usually cuts at Val at position 40 or/and at Ala at position 42. the γ-secretase(s) 
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(Fig. 2) is particularly interesting not only because of the novelty of the active site-
substrate reaction (i.e., within a membranous domain) but also due to the fact that another 
class of FAD known as presenilin-related FAD, appears to control the γ-secretase 
function, and that FAD mutations may effect the formation of Aβ (Scheuner et al., 1996). 
The γ-secretase processing is a heterogeneous event forming Aβ with different C termini, 
Aβ (1–40) or Aβ (1–42). The most common form is the significant high capacity of self 
aggregation of Aβ 42 variant. As compared to Aβ 40, Aβ 42 has a greater tendency to 
form fibrillary Aβ which displays a β-sheet conformation. Aggregation of these peptides 
are believed to initiate Aβ accumulation in all forms of the disease (Gandy and 
Greengard, 1994). The deposition of “seeding” Aβ 42 accelerates Aβ 40 accumulation 
and stimulates a cascade of processes leading to the formation of compact plaques and 
NFT followed by neuron death (Gandy and Greengard, 1994; Selkoe, 2001). In the 
normal neuronal tissue, secretases release predominantly the Aβ 40 fragment, which form 
diffuse plaques. The remaining soluble polypeptide APP is released in the extracellular 
environement. It has been suggested that soluble APP may play a trophic role in neuronal 
cells (Neve et al., 2000).   
  In addition to a neurotrophic role, the function of APP may include cellular adhesion 
and neuroprotection. The homology betweent the N-terminal domain of APP and the 
Kunitz class of serine-protease inhibitors (KPI), points to another potential function for 
APP (Kitaguchi et al., 1988). APP may act to inhibit serine protease in isoforms that 
contain the KPI domain.  Recently, a novel putative function of APP has been proposed 
in the trafficking of vesicles in axons (Zheng et al., 1998). Some investigators have 
proposed that the normal function of APP could be that of a membrane cargo receptor for 
conventional kinesin (kinesin I) by direct binding to the light kinesin (Kamal et al., 
2000). This hypothesis is interesting because several studies suggest that aberrant 
trafficking of APP may play a role in the pathogenesis of AD (Fassbender et al., 2004; 
Sinha and Lieberburg, 1999). APP may be a membrane cargo receptor for kinesin-I and 
might link kinesin-I to a particular subset of axonal transport vesicles. Moreover, these 
findings show a direct interaction of APP and the microtubule-based transport machinery. 
Thus, abnormal interactions between APP and kinesin-I might be one factor that plays a 
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role in determining the onset of AD, perhaps by blocking or otherwise interfering with 
normal axonal transport. 
  Although only about 1% of all familial Alzheimer’s disease cases are inherited in an 
autosomal dominant pattern, these cases are important for understanding the mechanism 
of the progressive cerebral Aβ deposition that occurs in all cases of AD. To date, three 
genes responsible for familial autosomal dominant AD have been identified in the human 
genome: APP gene, presenilin 1 (PS1) gene and presenilin 2 (PS2) gene. The best 
evidence causally linking APP to AD has been provided by the discovery of mutations 
within the APP coding sequence that segregate with disease phenotypes in autosomal 
dominant forms of familial AD. The gene for APP is localized on chromosome 21. 
Pathologic mutations within the sequence that codes for Aβ in the APP gene result in a 
higher Aβ production or an increase in Aβ self-agreggation and therefore in plaque 
deposition (Sahasrabudhe et al., 1992). Aβ1–42 accumulates in some brain regions such as 
cerebellum, striatum, and thalamus and is clearly implicated in the clinical syndrome of 
Alzheimer's disease (Braak et al., 1998; Nagy et al., 1998). 
  The most common familial AD is the British mutation, in which an isoleucine residue is 
substituted for a valine residue within the transmembrane domain, at a position two 
residues downstream from the carboxy-terminus of the Aβ domain (V717I) (Goate et al., 
1991). Another familial AD pedigree is the Swedish double mutation, in which the 
tandem missense mutations—Lys (K)—Met (M), Asn (N)—Leu (L) occur just upstream 
of the amino-terminus of the Aβ domain, (670 KM/671 NL) (Mullan et al., 1992). The 
effects of the APP mutations have been summarized in Table 1 (Hardy, 1997). To date, 
most of the data indicate that all APP mutations are clustered near the α-, β-, and γ-
secretase cleavage sites thereby demonstrating that they have a direct effect on APP 
processing and Aβ formation (Fig. 2). The majority of the mutations affect the activity of 
secretases leading to the overproduction of the amyloidogenic and toxic Aβ 42 peptide. 
However, the mutations in the two other known  
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Table 1. The known routes to Alzheimer disease 
Primary cause Route Final result 
Down syndrome More APP production More Aβ42(43) and more Aβ40
APP670/1 (Swedish) Potentiation of β-secretase More Aβ42(43) and more Aβ40
APP692 (Flemish) Inhibition of α-secretase More Aβ42(43) 
APP717 (British) Alteration of site of γ-secretase cut More Aβ42(43) 
PS1 mutations Subtle alteration of APP processing More Aβ42(43) 
PS2 mutations Subtle alteration of APP processing More Aβ42(43) 
pathogenic genes, PS 1 and PS 2 on chromosome 14 and 1, respectively, share the fact 
that they alter APP processing, leading to an increased production of the 42(43) amino 
acid peptide Aβ 42(43) (Citron et al., 1997). Thus, PS also play a critical role in γ-
cleavage of APP. However, multiple lines of evidence suggest that the proteins are 
essential for γ-secretase activity. Presenilins may also act as co-factors for γ-secretase or 
as modifiers of trafficking of APP derivatives and γ-secretase or as chaperone in the γ-
secretase complex that includes other elements like nicastrin. Thus, PS 1 and PS 2 may 
alter the proteolytic processing of APP and favor the production of the highly 
amyloidogenic APP fragment Aβ 42(43). 
  The Aβ itself may exert direct neurotoxic effects. SPs may promote oxidative damage to 
the neuron in several ways, including lipid peroxidation, protein oxidation, and formation 
of ROS (Butterfield et al., 2002). In brain tissue from AD patients, there is an increased 
level of markers of oxidative stress including oxidized proteins, membrane lipids, DNA, 
and nitrotyrosine immunoreactivity (Atwood et al., 1999). Aβ associated oxidation also 
interferes with glutamate transporter and glutamate synthetase, both of which modulate 
glutamate-induced excitotoxicity. 
1.4 Mechanisms of neuronal apoptosis in Alzheimer's disease 
  Research into the mechanism of cell death in AD have led to the understanding of how 
apoptosis and necrosis contribute to neurodegeneration (Kusiak et al., 1996; Wolozin and 
Behl, 2000). Apoptosis refers to a form of programmed cell death displaying 
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characteristic morphologic features that is executed by a series of cellular events 
involving the activation of caspases that actively kill the cell. Caspases are a family of 
cysteine proteases, some existing as proenzymes, which must be cleaved for activation, 
with the ability to initiate a cascade of cellular events that finally execute the 
characteristic features of apoptosis such as DNA cleavage, nuclear condensation, and 
blebbing of the plasma membrane.  
  In the nervous system and particularly during development, apoptosis appears to be 
triggered by trophic factor deprivation. The lack of activation of an intracellular pathway-
transducing trophic factor leads to caspase activation by complex mechanisms. Estévez 
and co-workers (Estevez et al., 1999; Estevez et al., 1998) showed evidence that trophic 
factor deprivation in motor neurons induces oxidative stress involving the production of 
ROS, which activate caspase-3. Neuronal death may also be triggered by extracellular 
death signals such as Fas- or p75NTR ligands that activate caspase-8 to initiate apoptosis.  
  Neuronal apoptosis is likely to occur in AD. Neuropathologic studies show an increased 
incidence of apoptotic neurons in postmortem samples from AD patients as compared to 
controls (Estevez et al., 1999). Signs of apoptosis in brains from AD patients include 
increased DNA damage, and caspase activity, and altered expression of other apoptotic-
related genes (Masliah et al., 1998). Studies on cell culture model systems indicate that 
the mechanism of apoptosis in AD is associated with increased oxidative stress, perturbed 
calcium homeostasis, mitochondrial dysfunction and caspase activation. In addition, Aβ 
has been shown to induce apoptosis in vitro by a mechanism involving altered 
intracellular Ca2+ metabolism (Mattson, 2000). Presenilins seem to play a role as 
modulators of neuronal apoptosis and mutation of presenilins results in an increased 
neuronal vulnerability to apoptosis (Yang et al., 1998).  
  Despite the evidence, some authors studying the toxicity of Aβ peptide advocate in 
favor of necrotic mechanisms rather than caspase-dependent apoptosis. Necrotic cell 
death is characterized by swelling of the cell followed by rupture of the plasma 
membrane and release of the cellular contents to the surrounding area. The necrotic tissue 
is eventually removed by inflammatory reactions. Aβ has been described to mediate 
necrotic processes by altering intracellular Ca2+ homeostasis and free radical formation. It 
appears that apoptosis and necrosis overlap in causing neuronal cell death in AD.  
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  Both extracellular deposition of Aβ and damaged neurons and neurites trigger chronic 
inflammatory reactions in the brain and activate a variety of protective inflammatory 
pathways (Akiyama et al., 2000; Bamberger and Landreth, 2002). However, the 
inflammatory reaction can also be harmful and the relative expression of different 
inflammatory factors can either promote or counteract neurodegenerative processes. 
Recent studies suggest that microglia and astrocytes are activated in response to 
inflammation and provide more fuel to the reaction by producing new mediators.  
2. Microglia  
  In 1932, del Rio-Hortega comprehensively described microglia, which are a distinct cell 
type within the central nervous system (CNS) with characteristic morphology and 
staining characteristics which differentiate them from other glial cells and neurons. 
Numerous studies in the last three decades, have generally supported the view that 
microglia derive from mesodermal precursor cells, possibly of hematopoietic lineage, that 
enter the brain during the embryonic and early postnatal phases of development (Cuadros 
and Navascues, 1998). Microglia, which may constitute as many as 12% of the cells in 
the CNS, are considered as the resident macrophage-like immune cells. In recent years, 
the advent of monoclonal antibodies has enabled the identification of cell surface 
determinants, and a more sophisticated identification of microglia. Microglia have a 
number of antigens normally associated with leucocytes and clusters-of-differentiation 
molecules. They are a derivative of a group of cells related to peripheral monocytes and 
macrophages, and in a sense, constitute the macrophages of the CNS. They act as 
immunocompetent defense cells that orchestrate the endogenous immune response of the 
CNS. Microglia also have phagocytic and scavenger properties. They are particularly 
sensitive to changes in their microenvironment, including exposure of the cell to bacteria, 
viruses, foreign proteins, cellular debris and abnormal cellular components (Akiyama et 
al., 2000; Bamberger and Landreth, 2002). They readily become activated to cause an 
inflammatory response. 
2.1 The roles of microglia  
  Microglia exist in a resting state as ramified cells in normal adult brain, but can be 
activated by a wide range of stimuli and factors during CNS injury. The effect of 
microglia on neurons depends on the activation state of the microglia (Kreutzberg, 1996). 
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Generally, Aβ triggers a microglial inflammatory response (Klegeris et al., 1994). In co-
culture with astrocytes or neurons, resting ramified microglia are characterized by small 
cell bodies with slender extended processes (Zhang and Fedoroff, 1996). Resting 
microglia have been shown to migrate toward plaques by chemotaxis, proliferate, and 
attain an activated state. During activation, they go through morphological changes, first 
taking a rod-shaped appearance with a characteristic swelling of the cell body. Retraction 
of cellular processes then follows and cells adopt an ameboid shape with accumulation of 
cytoplasmic vacuoles (Rogers and Lue, 2001). At this stage, microglia are activated and 
secrete growth factors (Kreutzberg, 1995), such as neuroprotective factors, transforming 
growth factor-β (TGF-β) (Giulian et al., 1994; Kreutzberg, 1996), β-fibroblast growth 
factor and pro-inflammatory mediators with neurotoxic activity, such as 1) ROS (El 
Khoury et al., 1996; Giulian et al., 1994); 2) cytokines, which are a heterogeneous group 
of small molecules that act in autocrine and paracrine fashion. They encompass several 
subfamilies, which include interleukins (ILs) like IL-1α, IL-1β, IL-6, IL-8, TNF-α, TGF-
β, monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-
1α (MIP-1α) and chemokines; (Giulian et al., 1994), IL-6, and TNF-α, are toxic to some 
cell types and can induce complement-mediated killing (Moore and Thanos, 1996; 
Rogers et al., 2002). 3) complement proteins; 4) excitatory amino acids; 5) fatty acid 
metabolites such as eicosanoids and quinolinic acid; and 6) proteolytic enzymes 
(Akiyama et al., 2000; Bamberger and Landreth, 2002). To what extent this microglial 
activation would be beneficial to neuronal survival and regeneration or deleterious to the 
neuronal network, is still under debate (Kreutzberg, 1996).  The activation of microglia, 
rather than being protective, may in fact result in further neurotoxicity. In this model, 
microglia appears to play at best a dual role, amplifying effects of inflammation and 
mediating cellular degeneration. Additionally, the opposing actions of microglia on 
neurons in vitro probably depends upon the presence of other glial cell-types, the 
composition of the culture medium, or the type of neurons used as target cells (Mallat and 
Chamak, 1994). Activation of microglia is characterized by changes in morphology, 
phenotype and behaviour including increased proliferation and recruitment to the site of 
injury (Aloisi, 1999; Aschner et al., 1999). Histological evidence has implicated 
microglia in AD brain as plaque-attacking scavenger cells, as sources of cytokines and 
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ROS (Giulian et al., 1996), as producers of Aβ (Frackowiak et al., 1992), and as secretors 
of complement proteins (Rogers et al., 1992). Activated microglia proliferate, exhibit 
phagocytic activity to remove infectious agents or remnants of dying brain tissue, and 
produce a number of secreted factors such as proteases and cytotoxic agents that induce 
death of neurons and demyelination of oligodendrocytes (Giulian, 1987; McGeer et al., 
1993). Therefore it is likely that the microglia surrounding SPs in AD brains are the main 
scavengers and removers of Aβ peptides from the brain (Giulian, 1987). 
2.2 Multiple pathways leading to microglial activation 
  The precise mechanism of neuronal damage mediated by microglia is only partially 
understood. Important clues relevant to the understanding of the pathogenesis of 
degenerative neurological disorders can be obtained by comparing the mode of action of 
a wide spectrum of potentially neurotoxic agents (Fig. 3).  
  
Fig. 3. Multiple pathways leading to microglial activation. (Liu and Hong, 2003) 
  At one end of the spectrum are those agents that appear to be totally incapable of 
directly killing neurons. In vitro microglia can be activated by lipopolysaccharide (LPS), 
a well-studied bacterial cell wall endotoxin. LPS is widely used as a powerful tool for the 
activation of microglia (Bronstein et al., 1995). It is now generally accepted that activated 
microglia contribute to the neurodegenerative process through the release of a variety of 
pro-inflammatory mediators and neurotoxic factors that exacerbate the degeneration of 
neurons (Akiyama et al., 2000; Bamberger and Landreth, 2002; McGeer and McGeer, 
2003). The activation of microglia by exposure to LPS results in apoptosis of neuronal 
cells in vitro. Studies using cell culture models have demonstrated that excessive 
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quantities of multiple factors produced by activated microglia can be deleterious to 
neurons, For example, Chao et al reported that the combination of IL-1 and TNF-α, but 
neither of the cytokines alone, induced the degeneration of cortical neurons (Chao et al., 
1995). Jeohn and colleagues have shown that the combination of IL-1, TNF-α, and 
interferon-γ work in synergy to induce degeneration of cortical neurons (Jeohn et al., 
1998). Recently, Xie et al showed that peroxynitrite, a possible product of superoxide and 
NO, is a major mediator of neurotoxicity induced by LPS or β-amyloid peptide (1-42) 
(Xie et al., 2002).  
  In contrast to the indirect action of LPS, certain agents are known to have a direct 
neurotoxic effect. Two experimental neurotoxins for dopaminergic neurons, namely 1-
methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and 6-hydroxydopamine (6-OHDA), 
are good examples. Direct damage to neurons by these agents causes reactive gliosis. 
(Cicchetti et al., 2002; Wu et al., 2002).  
  In addition to the direct and indirect toxins mentioned above, another group of agents 
that are known to be associated with various neurodegenerative diseases exhibit a "mixed 
mode" mechanism of neurotoxicity. These include Aβ, HIV coat protein gp120, prion 
protein-derived peptides, and the pesticide rotenone (Fig. 3). Recent studies have 
revealed that activation of microglia and the subsequent release of neurotoxic factors 
contribute to their neurotoxicity. For example, the potency of Aβ (1-42)-induced 
neurotoxicity on cultured cortical and mesencephalic neurons increased by severalfold in 
the presence of microglia (Qin et al., 2002). The enhanced neurotoxicity of Aβ (1-42) 
was attributed primarily to the activation of microglia and subsequent release of the 
superoxide free radical. The presence of microglia significantly enhanced its 
neurotoxicity, and the generation of oxygen free radicals appeared to underlie this 
increased toxicity (Gao et al., 2002). Similarly, the destruction of neurons by HIV gp120 
and prion proteins also involves the participation of activated microglia (Brown, 2001). 
Therefore, it appears highly probable that the overall neurotoxic effect of these mixed 
mode toxins include elements of both direct neurotoxicity and indirect toxicity through 
the activation of microglia.  
2.3 Microglia and Aβ 
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  The presence of activated microglia around Aβ represents a major characteristic feature 
of neuro-inflammation in AD brain (Streit, 2004). Current morphological studies 
emphasize the close relationship between microglial cells and SP, and they permit 
important inferences: 1) microglial activation in AD is profoundly associated with Aβ 
accumulation rather than another lesion; 2) in the early stages of disease, microglia are 
involved in depositing Aβ; 3) the persistence of Aβ deposition activates the microglia, 
and the task of removal becomes even more difficult by the localization of Aβ-associated 
factors such as apolipoprotein and perlecan, which may be secreted by microglia 
themselves (Miller et al., 1997); and 4) microglia mediate the transformation of diffuse to 
dense (compacted) plaques and serve as a means in Aβ fibril formation (Griffin et al., 
1998). Thus, on exposure to Aβ, microglia exhibit secretory, phagocytic, and chemotactic 
responses consistent with scavenger cell activity in a localized inflammatory setting. 
Though AD microglial secretory, phagocytic, and chemotactic activity have common and  
tightly linked stimuli (e.g., highly inert Aβ deposits), cell surface intermediaries (e.g., 
receptors, opsonins), and soluble intermediaries (e.g., cytokines, chemokines), the 
relationships between microglial cells and Aβ are only partially understood.  
  Virtually all studies indicate that Aβ deposits attract and activate microglia to produce 
inflammatory mediators. Some of these mediators feed back to induce further chemotaxis 
resulting in activation of the microglia, and others cause localized tissue damage. High 
concentrations of chemoattractants at the site of inflammation induce cytotoxic response 
that lead to formation of ROS (Hensley et al., 1994; Klegeris et al., 1994) and stimulate 
the synthesis and release of proinflammatory cytokines. Immunocytochemical markers of 
macrophages and leukocytes have produced differential patterns (Kalaria et al., 1996). 
The differential localization of the markers may reflect distinct maturational stages of the 
microglial cell, manifestation of the activation signal within certain cells, or variability in 
inflammatory response. These observations are consistent with established mechanisms 
of Aβ-activated microglia.  
  Although the mechanisms for Aβ-induced microglia responses are not clear, evidence 
exists that Aβ interacts with several other receptors present in microglia plasma 
membranes (El Khoury et al., 1996; Yan et al., 1996). These reports demonstrate that 
aggregated Aβ binds to the unrelated classes of receptors: 1) RAGE in neurons, microglia 
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and vascular endothelial cells; 2) M-CSF in microglia; 3) α2 -macroglobulin receptor/low 
density lipoprotein receptor-related protein (LRP) in microglia (Marzolo et al., 2000). 
These receptors are thought to mediate endocytosis or transcytosis of macromolecules. 
However, no signal-transduction pathway has been linked to these receptors and it is not 
clear whether binding of Aβ to either of these receptors is directly linked to any observed 
functional responses.  
  Once at the site of Aβ deposition, activated microglia attempt to phagocytose and clear 
out Aβ, perhaps leading to further activation. Griffin and colleagues (Griffin et al., 1998) 
have suggested that IL-1 and Aβ are essential mediators of a “self-propagating 
mechanism” or “reinforcing feedback loop,” which may explain the progressive neuro-
degeneration in AD. Chemokines may play an important role in microglial migration and 
accumulation at sites of Aβ deposition (Xia and Hyman, 1999). After exposure to Aβ, for 
example, activated microglia upregulate their production of the chemokines IL-1β, IL-6, 
IL-8, TNF-α, MIP-1α, MIP-1β and monocyte chemoattractant protein-1 (MCP-1) ((Meda 
et al., 1999; Rogers and Lue, 2001; Yates et al., 2000). These can attract microglial 
migration to Aβ deposits.  
  Once at the site of Aβ deposition, and activated by exposure to Aβ, studies suggest that 
microglia may phagocytose Aβ fibrils. This is not unexpected as microglia clearly have 
phagocytic capabilities (Frautschy et al., 1992; Weldon et al., 1998). In addition, Aβ 
aggregates have precisely the properties that are conducive to phagocytosis; that if 
abnormally deposited, becomes chronic and highly insoluble in the form of cross-β-
pleated protein. It is now apparent that Aβ interacts in a specific manner with microglia 
and that aggregated or fibrillar Aβ may be taken up via specific receptors (Paresce et al., 
1996; Yan et al., 1996). This is substantiated by the evidence that the macrophage 
scavenger receptor, a multifunctional receptor for oxidized low-density lipoprotein, is 
immunolocalized in microglia but not in astrocytes associated with Aβ deposits (Christie 
et al., 1996). Opsonin-independent, cell surface candidates include the formyl peptide 
receptor (FPR) (Lorton et al., 2000), CD14 receptor (Fassbender et al., 2004; Wright et 
al., 1990), RAGE and macrophage colony-stimulating factor (M-CSF) (Lue et al., 2001; 
Yan et al., 1996), all of which have Aβ as a ligand and all of which are expressed by 
microglia (Lorton et al., 2000; Yan et al., 1996). In addition, Classical complement 
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opsonins, including C1q and C3a, CR3 are up regulated at sites of Aβ deposition, and the 
microglia clustered at such sites bear receptors for them (Akiyama et al., 2000). These 
receptors can bind Aβ and trigger cellular activation. The complement system (Quigg, 
2002) has components to carry out four major functions, namely, recognition, 
opsonization, inflammatory stimulation through anaphylatoxins and direct killing through 
the membrane attack complex (MAC). 
  Phagocyte complement receptors occur in two distinct structural forms. Complement 
receptor type 1 (CR1) is a monomeric transmembrane protein that binds C3b and C4b but 
not C3bi (Ahearn and Fearon, 1989). Amplification takes place through a cascade of 
proteases (C1r, C1s, C4, C2 and C3). CR1 possesses complement regulatory activity and 
can mediate phagocytosis of bound particles, but its capacity for signal transduction or 
cell activation has not been thoroughly characterized. CR3 and CR4 are heterodimeric 
proteins of the integrin superfamily. They are heterodimers that contain identical β 
subunits (CD18, 95kDa or β2 integrin) and distinct  subunits (CD11b, 165 kDa or αM 
integrin and CD11c or αX integrin). CR3 and CR4 bind C3bi, and CR3 also contains a 
glycan binding site (lectin site) (Thornton et al., 1996). CR3 expressed on the surface of 
monocytes, macrophages and neutrophils, is involved in the binding and phagocytosis. If 
the complement system is fully activated, it proceeds to assemble the terminal 
components (C5b, C6, C7, C8 and C9) into the lytic macromolecule C5b-9, known as the 
MAC. First identified as the macrophage surface marker Mac-1, was later shown to 
function both as an adhesion molecule and a C3bi receptor (Beller et al., 1982; Springer 
et al., 1979). As an adhesion molecule, it mediates the diapedesis of leukocytes via 
generation of a high affinity binding site for endothelial cell ICAM-1 (CD54) (Hogg and 
Berlin, 1995). Alternatively, when it functions as an C3bi receptor, it mediates 
phagocytosis and degranulation in response to micro-organisms or immune complexes 
opsonized with C3bi (Xia and Ross, 1999).  
  Previous studies mapped the lectin site of CD11b by analysis of ß-glucan-FITC staining 
of Chinese Hamster ovary (CHO) cells expressing recombinant chimeras between CD11b 
and CD11c in association with CD18. The prior attachment of the small SZP molecule to 
CR3 was also shown to block or disrupt mAb-defined epitopes of CD11b located within 
the C-terminal region, while having no effect on epitopes within the I domain (Thornton 
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et al., 1996). Although these data localized the lectin site to a region in the C-terminus of 
CD11b, it was unclear whether the lectin site included portions of CD18, or whether 
lectin site function required a conformation of CD11b that was induced by its association 
with CD18.  
  A baculovirus system has been used to express various truncated rCD11b proteins at 
high levels in insect cells without associated CD18. Analysis of the lectin activity of these 
rCD11b proteins using flow cytometry and radioactive binding assays suggested that the 
lectin site of CR3 was probably entirely within the C-terminal region of CD11b between 
residues 400-1092 and did not require the I domain or CD18 to express its high affinity 
binding site for soluble polysaccharides such as β-glucans (Xia and Ross, 1999). Thus, 
CD11b binds to CR3 receptor and prevents its cleavage, and inhibits activation of both 
classical and alternative complement pathways (Furlong et al., 2000). 
  In the classic pathway, complement is activated by the binding of an antibody of the 
immunoglobulin M or immunoglobulin G class to a foreign particle. The alternate 
pathway is activated directly by microorganisms and does not require antibodies. For 
both the classical and alternative pathway, MAC acts as the terminal cytolytic 
component, which can kill organisms directly by disrupting the integrity of the 
organism's membrane. Activation of the complement system can result in activation of 
opsonins, the adhering proteins of foreign particles for destruction by phagocytes. 
Finally, complement activation can lead to activation of proteins that act as chemo-
attractants for polymorphonuclear leucocytes. 
  Over-expression and activation of the complement system has been shown to occur in 
an Alzheimer brain. Complement regulators, such as C1 inhibitor and CD59 that protect 
the host cell against the damage produced by an activated complement system, have not 
been shown to significantly inhibit complement activation in AD brains (Yasojima et al., 
1999). Activation of the classical complement system in the CNS may not depend on 
antibodies, as traditionally thought. The classic inflammatory response (immunoglobulin 
and leucocyte infiltration) is absent. However, Aβ appear to activate the complement 
pathway in a similar fashion to immunoglobulin. Aβ can directly bind and activate the 
classic complement cytolytic pathway in the brain in the absence of antibodies in areas of 
the brain associated with AD pathology (Bradt et al., 1998). Aβ has been implicated with 
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the induction and formation of the activated C4 and C3 fragment proteins of the classical 
complement system (Webster et al., 1997). The classic complement pathway is normally 
initiated by the binding of C1q proteins to immunoglobulins, but immunoglobulins are 
virtually absent in the brain. Therefore, it is significant that Aβ1 16 has a high affinity 
for C1q protein and that aggregated complexes containing this segment bind strongly to 
the microglial C1q receptor (Eikelenboom and Veerhuis, 1996). It is the step thought to 
initiate activation of microglia. It is not known if Aβ can directly act on the CR3 receptor. 
The complement cascade can also be activated by other up-regulated factors in the 
affected regions of the AD brain, including the pentraxins, amyloid P (AP) and C-
reactive protein (CRP) (McGeer et al., 2001). 
  CD14, a 55 kDa phosphatidylinositol glycan-linked membrane protein, is best known 
and characterized for having a high-affinity as a major surface receptor for LPS that is 
preferentially expressed on monocytes and macrophages. The binding of CD14 with LPS 
is catalysed by LPS-binding protein (LBP). The toll-like-receptors have also been 
implicated in the transduction of CD14-LPS signals. Similar to other GPI-anchored 
proteins, soluble CD14 can be released from the cell surface by phosphatidyinositol-
specific phospholipase C. Soluble CD14 has been detected in serum and body fluids. 
High concentrations of soluble CD14 have been shown to inhibit LPS-mediated 
responses. However, soluble CD14 can also potentiate LPS responses in cells that do not 
express cell surface CD14 (Stelter, 2000; Wright et al., 1990). At low doses of LPS (< 10 
ng/ml), LPS-induced signaling and macrophage functional activation is completely 
blocked by anti-CD14 monoclonal antibody (mAb), indicating that CD14 predominantly 
acts as the LPS receptor for macrophage activation. On the other hand, at higher doses of 
LPS (> 10 ng/ml) anti-CD14 mAbs do not block LPS-induced signaling and macrophage 
functional activation, suggesting that a CD14-independent mechanism of LPS stimulation 
exists (Haziot et al., 1996; Nishijima et al., 1994). Thus CD14 is considered to be a 
primary binding site for LPS. It is unclear whether CD14 is capable of mediating 
phagocytosis in the absence of another membrane protein. As we know, LPS can activate 
microglia which in turn induces apoptosis or neuro-degeneration. Aβ displays a similar 
activation of microglia. Thus, it is not clear whether Aβ can activate microglia through 
CD14 receptor. Polymorphonuclear leucocytes (neutrophils) play a key role in the host 
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defence against micro-organisms. Their migration is governed by chemoattractants, the 
most important of which is fMLP (N-formyl-L-methionyl-L-leucyl-L-phenylalanine; 
‘chemotactic peptide’) (Boulay et al., 1997). Two functional fMLP receptors have been 
cloned and characterized, namely FPR (N-formyl-L-methionyl-L-leucyl-L-phenylalanine) 
and FPR-L1 (FPR-like 1), with a high (FPR) and a low affinity (FPR-L1) for fMLP 
respectively and with 69% amino acid sequence similarity (Hartt et al., 1999; 
Quehenberger et al., 1993). fMLP is a known activator of PLC (phospholipase C) (Li et 
al., 2000), PI3K (phosphoinositide 3-kinase) (Stephens et al., 1997) and PLD 
(phospholipase D) (Rossi et al., 1990). The resulting second messengers act on various 
intracellular kinases, including PKC (protein kinase C). PKC is a family of isotypes 
classified into three groups on the basis of their structure and mode of activation (Dekker 
and Parker, 1994), conventional PKCs (cPKCs; PKC-a, -bI, -bII and -g), novel PKCs 
(nPKCs; PKC-d, -e, -h and -q) and atypical PKCs (aPKCs; PKC-z and -l). 
  To differentiate between the two receptors, a peptide antagonist, t-Boc, was used (Freer 
et al., 1980). t-Boc is known to block the FPR over expressed in Sf9 cells (Wenzel-Seifert 
et al., 1998) and the endogenous FPR in neutrophils (Dahlgren et al., 2000), both of 
which have a high affinity for fMLP. T-Boc can differentiate between a high- and a low-
affinity fMLP receptor on neutrophils, the high-affinity receptor most probably being 
FPR. The low-affinity receptor could be FPR-L1, based on the fact that its mouse 
orthologue (FPR2) has a low affinity for fMLP (Hartt et al., 1999) and that the activation 
of FPR-L1 by a synthetic peptide agonist is insensitive to t-Boc (Dahlgren et al., 2000). 
Similar differences in fMLP receptor subtypes have been suggested in mouse neutrophils 
where two distinct optima of chemoattractant concentration have been shown to induce 
chemotaxis. 
  Aβ has chemokine-like properties and may act via formyl chemotactic receptors (FPR) 
to induce pathophysiologically important functional changes in AD. Davis et al (Davis et 
al., 1992) demonstrated that Aβ is a chemoattractant for monocytes, macrophages, and 
microglia. Aβ peptides also produce ROS that indicate activation of cytotoxic responses 
in macrophages (Hensley et al., 1994; Klegeris et al., 1994). 
  Comparison of the amino acid sequences of Aβ and the best studied chemoattractant, 
formyl-met-leu-phe peptide (fMLP) reveals that the two peptides share similar 
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hydrophobic properties and structural properties and that they have several amino acid 
sequences in common. Similar to Aβ, fMLP and its analogues adopt a β-pleated sheet 
conformation that tends to aggregate in solution. The three carboxyterminal amino acids 
of Aβ resemble, in reverse order, the amino acid sequence of fMLP. However, the amino-
terminal methionine is modified by formylation and there is a non-conserved substitution 
of phenylalanine for glycine in the fMLP sequence. 
  As already summarized, the processes of microglial chemotaxis, activation, and 
phagocytosis of Aβ are all inextricably linked by the same receptors and soluble 
intermediates, as well as by the same common stimulus i.e. Aβ. The proposed process of 
microglial activation, chemotaxis, and phagocytosis of Aβ are as follows : 1) Microglia 
proximal to Aβ deposits are activated by multiple mechanisms, which may include Aβ 
binding to the FPR, CD14, CR3 and RAGE, all of which have Aβ as a ligand, but it is not 
known which ones are important in neurodegeneration. 2) With activation, the microglia 
become less ramified and more ameboid in appearance, and they exhibit enhanced MHC 
II cell surface immunoreactivity. Activation also increases microglial production of 
cytokines, chemokines, and other soluble inflammatory factors, many of which (e.g. 
MCP-1, MIP-1α, IL-8, M-CSF, C3) stimulate chemotaxis and activate of microglia distal 
to the Aβ deposit. 3) Microglial activation is essential for and intrinsic to the 
phagocytosis of Aβ. After ingestion of Aβ by microglia, M-CSF over-expressed by the 
microglia in the vicinity of Aβ deposits can result in enhanced phagocytosis of opsonized 
Aβ with improved clearance of the deposits (Mitrasinovic and Murphy, 2003). 
  In addition, the microglia themselves may be a source of Aβ production in the AD brain 
where they have been shown to secrete Aβ under the influence of Aβ or pro-
inflammatory stimuli (Bitting et al., 1996). The production of Aβ by microglia is only a 
small part of the total Aβ since the major source of Aβ production comes from neurons. 
3. The aim of study 
  It was the immediate aim of this thesis work to establish a simple cellular model of the 
neuroinflammatory component of Alzheimer's disease. We reasoned that the coculture of 
microglia with APP-expressing neuronal cells might provide such a model. The long term 
aim of the work is an increased understanding of the mechanisms underlying 
neuroinflammation and particular microglia activation in AD-associated 
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neurodegeneration and also to use the model for the development and the study of novel 
treatment approaches. In this model, it would be possible to refine and develop some anti-
inflammatory approaches and some neuro-protective reagents such as antioxidants; anti 
TNF-α reagents; lowing lipids drugs; phosphodiesterase inhibitor and some Chinese 
traditional herbs. We hypothesize that inhibition of ROS generation by agents could be a 
highly effective approach compared with conventional therapeutic strategies that inhibit 
the production of individual cytotoxic factors. Similarly, agents targeted at the receptors 
involved in the interaction between amyloid fibrils and microglia or macrophages may 
have therapeutic potential.  
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Materials and Methods 
Reagents  
  Cell culture media, fetal bovine serum, penicillin, streptomycin were obtained from 
Gibco BRL, (Paisley, Scotland). LPS from Escherichia coli sero-type O55:B5; L-ascorbic 
acid (Vit C) free acid cell culture; Tocopherol (Vit E); Hygromycine B; Nitro Blue 
Tetrazolium (NBT) tablet; Diphenyleneiodonium chloride (DPI), propidium iodide, 
RNAse were from Sigma and Fluka (Buchs, Switzerland). The stock solutions of the 
following substances were stored in working aliquots at -20 °C. LPS and Vit C were 
dissolved in distilled water at stock concentrations of 1 mg/ml and 100 mM, respectively. 
Vit E was dissolved in 100% ethanol at a stock concentration of 400 mM. DPI was 
dissolved in l ml DMSO at a stock concentration of 32 mM. All of them were diluted into 
culture medium immediately before use. Murine GM-CSF (Granulocyte/Macrophage 
Colony-Stimulating Factor, CSF-2, MGI-1 GM, pluripoietin-α) was obtained from 
PeproTech EC Ltd (United Kingdom) and Catalase and Superoxide dimutase (SOD) were 
from Roche (Germany). The stock solutions of the following substances were stored in 
working aliquots at -20 °C. SOD was dissolved in PBS at a stock concentration of 50'000 
U/ml and Catalase was dissolved in 0.1 M pH 7.6 phosphate buffer solution (NaH2PO4 
and Na2HPO4) at a stock concentration of 200'000 U/ml. The mouse anti-amyloid β-
precursor protein (695 aa) was purchased from ZYMED laboratory, INC (San Francisco, 
USA).  
DNA constructions  
  The plasmids poCK751 APP (wild-type, wt), pCMV751 APP (Swedish; 
K670M/N671L), and pCMV751 (London; V717I) (triple mutants, 3m) were kind gift 
from Dr. L. McConlogue. The construct pHR’CMV-APP-wt was created by ligation of 
the fragment BclI–HpaI from poCK751 APP (wt) into a BamHI–NheI–cleaved pHR’ 
cytomegalovirus (CMV)-GFP-W transfer vector. The construct pHR’CMV-APP-3m was 
created by ligation of the fragment SnaBI–SpeI from poCK751 APP-3m 
(K670M/N671L/V717I) into a SnaBI–NheI–cleaved pHR’ (CMV)-GFP-W transfer 
vector (Zufferey et al., 1999). They were further confirmed by sequencing. 
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Cell cultures 
  a) Human SH-SY5Y neuroblastoma cell line were cultured in RPMI 1640 medium 
supplemented with 10% fetal bovine serum, penicillin (100 units/ml), and streptomycin 
(100 µg/ml), called complete RPMI medium. For differentiation, the density of 105 cells 
were grown in 10-cm cell culture plates for 24 hrs at 37 °C in a humidified 5 % CO2, 95 
% air atmosphere incubator and the medium was changed every two days, and the cells 
were routinely tested for mycoplasma contamination that passed regularly. The Green 
Fluorescent Protein (GFP) was expressed in the human SH-SY5Y neuroblastoma cell 
line, which can yield a homogeneous cell line with a neuronal morphology and function, 
and can be determined easily by the detection of GFP fluorescence (Vilhardt et al., 2002). 
  b) GM-CSF-dependent Ra 2 microglial cells generated by spontaneous immortalization 
of primary mouse microglia, which closely resemble primary rodent microglia in 
morphology, many phagocyte functions, and in expression of hematopoietic cell-specific 
molecules (Inoue et al., 1999; Kanzawa et al., 2000). Ra 2 cells were cultured in 10-cm 
cell culture plates with Eagle`s minimal essential medium supplemented with 10% fetal 
bovine serum, penicillin (100 units/ml), streptomycin (100 µg/ml) and glucose (2 g/L), 
GM-CSF (1 ng/ml), insulin (5 µg/ml) in the final concentration, named Ra 2 medium. For 
differentiation, cells were grown for 24 hrs at 37 °C in a humidified 5 % CO2, 95 % air 
atmosphere incubator and the medium was changed every three-forth days, and passed 
regularly according to an appropriate density of cells (about 60-80 % 
confluence) (Vilhardt et al., 2002).  
  c) The myeloid cell lines include wild-type of PLB-985 cells called as PLB-985-wt cells 
and a PLB-985 X-CGD cell line, in which the gp91phox gene was disrupted by 
homologous recombination (Zhen et al., 1993). These were maintained in RPMI 1640 
medium supplemented with 10 % fetal bovine serum, penicillin (100 units/ml) and 
streptomycin (100 µg/ml). For differentiation, the density of 105 cells were grown in a 
stationary suspension culture medium in 15 ml in 25-cm2 flask which was standing for 24 
hrs at 37 °C in a humidified 5 % CO2, 95 % air atmosphere incubator and the cells were 
grown at logarithmic rate and passaged twice a week at a ratio 1:3 dilution as previously 
described (Tucker et al., 1987). Hygromycin B with a concentration of 100 µg/ml was 
added into the culture medium for the disruption of the gp91phox gene in PLB-985 X-
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CGD cells. Optimal concentrations of 1.25% Me2SO (dimethyl sulfoxide, DMSO) were 
added to PLB-985-wt and PLB-985 X-CGD cells to induce differentiation into 
granulocyte-like cells. Differentiation was induced for 6 days and after 3 days of 
incubation, the fresh medium with the same concentration of Me2SO was changed (Dana 
et al., 1998). The cell viability was assessed by trypan blue exclusion using a 
hemocytometer. Then, the differentiated cells acquired brisk respiratory burst activity, 
that as assayed by NBT test, could be used for co-culture.  
Co-culture of human SH-SY5Y neuroblastoma cell line and Ra 2 microglial cell line  
  For the mixed neuroblastoma-microglia co-cultures, GFP transduced SH-SY5Y cells 
were seeded in 24-multiwell plates with a density of 9'000 cells / well in 1 ml complete 
RPMI medium. One day later, the medium was removed and Ra 2 microglial cells with a 
density of 90'000 cells / well were added to GFP expressing SH-SY5Y cells cultures in 1 
ml of 50 % (v/v) of complete RPMI medium and Ra 2 medium respectively. 24 hrs later, 
microglia in co-cultures were then activated by exposure to LPS at a final concentration 
of 0.1 µg/ml for 48hrs in 1 ml of 50 % (v/v) of complete RPMI medium and Ra 2 
medium. After the incubation time, cells were fixed and the number of remaining cells 
was determined under a fluorescent microscope at 40 X magnification by counting the 
number of GFP-positive cells in four random fields on the coverslip per condition to 
achieve an average counting per field and compared with a control in co-culture (not 
activated by LPS). The similar independent experiments were repeated twice. 
Co-culture of GFP/APP-3m expressing SH-SY5Y neuroblastoma cell line and PLB-
985 cell line  
  GFP/APP-3m expressing SH-SY5Y cells were co-cultured with PLB-985-wt cells or 
PLB-985 X-CGD cells, respectively. GFP/APP-3m transduced SH-SY5Y neuroblastoma 
cells were seeded in 24-multiwell plates with a density of 15'000 cells / well in 1 ml 
complete RPMI medium. One day later, the medium was discarded and the differentiated 
PLB-985-wt cells or PLB-985 X-CGD cells with a different number of cells / well was 
added in 1 ml of complete RPMI medium. After 48 hrs incubation, cells were fixed and 
the number of remaining cells was determined under a fluorescent microscope at 40 X 
magnification by counting the number of GFP fluorescent cells in four random fields on 
the coverslip per condition to achieve an average counting per field and compared with a 
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control in co-culture (not activated by APP). The similar independent experiments were 
repeated twice. 
Lentivirus production and transduction of APP in the human SH-SY5Y 
neuroblastoma cell line 
  Human neuroblastoma cell line was transduced with a HIV-1 based lentiviral vector 
(pHR’) as previously described (Naldini et al., 1996; Zufferey et al., 1997), containing 
either the green fluorescent protein (GFP), APP-wt or APP-3m coding sequences under 
the CMV promoter. Briefly, the human SH-SY5Y neuroblastoma cells were infected with 
an APP-wt (PCMV751 APP wt) or APP-3m (British mutation—pCMV751 and Swedish double 
mutation—pCMV751). The viral particles were produced by transient transfection in 293T 
cells as previously described (Dull et al., 1998). The viral supernatant-containing medium 
was collected after 48 hrs, filtered through 0.45 µM pore-sized polyethersulfone 
membrane and 1 ml was subsequently added to target cells. The virus was subsequently 
added to APP-wt or APP-3m target cells (human SH-SY5Y neuroblastoma cells) in 6-
well or 60-mm culture dishes in doses ranging from 250, 500 and 1'000 µl. Estimated 
virus titers of the concentrated stock ranged from 2 × 107 to 109 number of transducing 
units per ml (NTU/ml) of freshly prepared virus. The virus was left on the cells for 3-4 
days with the addition of fresh medium on day 2. For differentiation of human SH-SY5Y 
neuroblastoma cells harbouring APP-wt or APP-3m, the cells were passaged and grown 
in 10-cm cell culture plates for 24 hrs at 37 °C in a humidified 5 % CO2, 95 % air 
atmosphere incubator and the medium was changed every two days. 
Immunofluorescence of APP 
  After infection, the APP-wt or APP-3m expressing SH-SY5Y neuroblastoma cells were 
grown on coverslips in 6-well culture dishes for 24 hrs and were fixed in 2 % 
paraformaldehyde (w/v) in HBSS solution for 30 min. The coverslips were washed once 
for 5 min with HBSS, permeated with HBSS solution supplement with 0.5 % Triton X-
100 (v/v) for 30 min at room temperature, and then, washed once with 1 % FCS 
(blocking buffer) in HBSS. After incubation with monoclonal mouse anti-β amyloid 
precursor protein (695 aa) antibody (ZYMED laboratory, INC San Francisco, USA) 
diluted in 1: 100 in blocking buffer for 45 min at room temperature. The cells were 
washed twice with the blocking buffer, subsequently incubated with the secondary rabbit 
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anti-mouse antibody (Alexa 555) diluted in 1: 1'000 in blocking buffer for 45 min at 
room temperature (Molecular probes). Stained cells were visualized and taken in photos 
under a Zeiss axioplan microscope equipped for epifluorescence at 40 x magnification. 
Five random fields were counted from each condition, and the data were expressed as the 
percentage ratio of stained cells to total cells. Based on the results of 
immunofluorescence of APP, the 100 % infection of the human SH-SY5Y neuroblastoma 
cells with 500 µl of virus with APP-wt or APP-3m was selected and differentiated 
continuously. Then, GFP coding sequences driven by the CMV promotor was expressed 
again in the human SH-SY5Y neuroblastoma cells harbouring APP-wt or APP-3m. Thus, 
a stable GFP/APP-wt or GFP/APP-3m expressing SH-SY5Y cells was generated.  
Electrophoresis and Western blotting 
  Expression of human APP was determined by western blot analysis as previously 
described (Arai et al., 1992; Tomita et al., 1999). Briefly, cell lysates were collected 
using lysis buffer which contained 1% Triton X-100 in 50 mM NaCl, 10 mM MgCl2, 1 
mM EGTA, 50 mM Tris-HCl pH 7.4, containing protease inhibitor mixture (Roche 
Diagnostics) and ortho-vanadate in 1mM. After sonication, Bradford protein quantitation 
was performed (Bio-Rad). Samples of equal protein quantity (20 µg) were separated on 
10 % SDS-PAGE gels, and transferred to polyvinylidene difluoride membranes for 
western blotting according to standard techniques. After blocking for 1 hour, the 
membranes were incubated at room temperature with monoclonal mouse anti-β amyloid 
precursor protein (695 aa) antibody (ZYMED laboratory, INC San Francisco, USA) ( 
1:1'000 dilution ) for 2 hours. Blots were then washed three times for 5 min with PBS and 
0.05 % Tween 20. Then, the membranes were further blocked for 30 min (blocking 
duffer—5% milk, 0.05% Tween 20 in PBS) and incubated at room temperature with 
horseradish peroxidase-conjugated anti-mouse secondary antibody (1:10'000 dilution) for 
1 hr, developed with Lumiglo Chemiluminescent Detection Reagents (Cell Signaling) 
and exposed to film (Hyperfilm-ECL, Amersham). Blots shown were one of the three 
independent experiments performed. 
Cell culture of GFP/APP expressing SH-SY5Y neuroblastoma cells  
  The transduced SH-SY5Y neuroblastoma cell harbouring GFP/APP-wt or GFP/APP-3m 
was cultured by the method described above. They could then yield the stable 
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homogeneous cell line and could then be determined easily by the detection of GFP 
fluorescence. 
Co-culture of GFP/APP expressing SH-SY5Y cells and Ra 2 microglial cells  
  GFP/APP-wt or GFP/APP-3m cells were seeded in 24-multiwell plates with a density of 
12'000 cells / well (APP-wt) or 15'000 cells / well (APP-3m) in 1 ml complete RPMI 
medium. One day later, the medium was removed and Ra 2 microglial cells with a 
density of 150'000 cells / well (APP-wt) or 110'000 cells / well (APP-3m) were added in 
1 ml of 50 % (v/v) of complete RPMI medium and Ra 2 medium. After incubation for 48 
hrs, cells were fixed and the number of remaining cells was determined under a 
fluorescent microscope under 40 x magnification by counting the number of GFP-
positive cells in four random fields on the coverslip per condition to achieve an average 
counting per field and compared with a control co-culture. Two independent experiments 
were performed. 
Measurement of superoxide anion and NBT staining 
  The production of superoxide anion was measured by NBT method as described before 
(Dana et al., 1998). The co-cultures of comtrol cells or GFP/APP expressing SH-SY5Y 
cells with Ra 2 microglial cell line were performed as previously indicated. 1 µM DPI 
was added immediately after adding Ra 2 cells. NBT assay was performed during an 
incubation period of 2 hrs. The medium was remained in 100 µl and 100 µl of 1 mg/ml 
NBT solution was added into the well. The cells were incubated in the incubator for 30-
45 min and visualized in the presence of blue-black precipitates inside the cells and 
photos were taken under a 10 X objective using a Nikon eclipse TE300 microscope 
equipped for epifluorescence.  
Effects of ROS scavengers and antioxidants 
  APP-3m expressing SH-SY5Y cells were seeded in 24-multiwell plates with a density 
of 15'000 cells / well in 1 ml complete RPMI medium. One day after the seeding, the 
medium with or without 500 U/ml SOD plus 3'000 U/ml catalase or 75 µM Vit C plus 
100 µM Vit E were replaced in the culture. After an incubation period of 48 hrs, the SH-
SY5Y cells were fixed and the number of cells was determined by accounting number of 
GFP fluorescence in four randomized fields (40 X magnification) on the coverslip per 
condition to achieve an average counting per field and compared with a control. Two 
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independent experiments were performed again. 
  In the co-culture of APP-3m expressing SH-SY5Y cells with ROS scavengers, APP-3m 
expressing SH-SY5Y cells were seeded in 24-multiwell plates with a density of 15'000 
cells / well in 1 ml complete RPMI medium. After adding Ra 2 cells in the density of 
110'000 cells / well into the medium, 500 U/ml SOD plus 3'000 U/ml Catalase or 75 µM 
Vit C plus 100 µM Vit E was simultaneously added into the medium, respectively. They 
were used in parallel cultures as control. The following 2 days, cells were fixed and the 
number of remaining cells was determined under a fluorescent microscope at 40 X 
magnification by counting the number of GFP-positive cells in four random fields on the 
coverslip per condition to achieve an average counting per field and compared with a 
control. The similar independent experiments were repeated twice. 
  Control cells and APP-3m expressing human SH-SY5Y neuroblastoma cells were 
seeded in 6-wells plate with a density of 60'000 cells / well for a duplicate in 2 ml 
complete RPMI medium, respectively. One day later, the medium was removed. After 
adding Ra 2 cells in the density of 1'200'000 cells / well into 2 ml of 50 % (v/v) of 
complete RPMI medium and Ra 2 medium, 500 U/ml SOD plus 3'000 U/ml Catalase or 
75 µM Vit C plus 100 µM Vit E were simultaneously added into the medium, 
respectively. After incubation for 48 hrs, the cells were washed with HBSS solution and 
detached with PBS solution, then collected the cell solution and centrifuged it, then 
removed the supernatant and added 0.5 ml of 0.1% (BSA + 0.1% sodium azide in PBS 
solution). The number of harvested cells were then immeidately analyzed by a FACSscan 
flow cytometer (Becton Dickinson Mountain View, CA). The same independent 
experiment had been repeated twice 
Co-culture of control and GFP/APP expressing SH-SY5Y cells with hydrogen 
peroxide 
  Control cells and APP-3m expressing human SH-SY5Y neuroblastoma cells were 
seeded in 6-wells plate with a density of 60'000 cells / well for a duplicate in 2 ml 
complete RPMI medium, respectively. One day later, the medium was removed and 
different concentrations of hydrogen peroxide (µM) were added to a fresh medium. After 
incubation for 48 hrs, the cells were washed with HBSS solution and detached with PBS 
solution, then collected the cell solution and centrifuged it, then removed the supernatant 
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and added 0.5 ml of 0.1% (BSA + 0.1% sodium azide in PBS solution). The number of 
harvested cells were then immeidately analyzed by a FACSscan flow cytometer (Becton 
Dickinson Mountain View, CA). The same independent experiment had been repeated 
twice 
Cell cycle analysis 
  DNA content of wild-type of human SH-SY5Y neuroblastoma cells, GFP-expressing 
human SH-SY5Y neuroblastoma cell, GFP/APP-wt and APP-3m expressing human SH-
SY5Y neuroblastoma cells were determined by propidium iodide (PI) staining of DNA 
and FACS analysis. Each types of cells was seeded in the density of 360'000 cells in 10-
cm cultured dish. After incubation of 48 hrs, cells were washed in PBS and centrifuged at 
1000 rpm X 5 min. Cells were resuspended in 250 µl of ice-cold 100 % ethanol and stand 
on ice for 15 min. Then cells were centrifuged at 2500 rpm X 10 min. The cells pellet 
was resuspended in 125 µl stocked solution of propidium iodide (final concentration: 
62.5 Unit) and incubated in 37 °C water bath for 15 min, and subsequently exposed to 
125 µl of PI stain solution (final concentration: 25 µg/ml) for 30 min at 4 °C. The cells 
were analysed on a FACSCalibur flow cytometer (Becton Dicknson). Cell cycle analysis 
was carried out with Cell Quest software (Becton Dicknson). 
Statistical analysis 
  All quantitative data were shown as mean values from at least two to three independent 
experiments. The percentages of GFP expressing cells were calculated and expressed 
with the average value ± SEM. The data was analysed using Student's t-test for statistical 
comparison. A p-value < 0.05 was considered statisticaly significant. 
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Results 
 
The toxic effects of LPS-activated microglial cells on human SH-SY5Y 
neuroblastoma cells  
  We co-cultured the human SH-SY5Y neuroblastoma cells with Ra 2 microglial cells to 
determine whether microglia activated by LPS directly cause neuronal death or not. In the 
absence of Ra 2 microglial cells or LPS, there was no toxicity on SH-SY5Y 
neuroblastoma cells. After activation of Ra 2 microglias by LPS for 48 hrs, SH-SY5Y 
cells could be killed in the co-culture system. It demonstrated that neuroblastoma cells 
death required microglial activation. LPS-activated microglia could trigger the release of 
mediators or factors, causing neurotoxicity. The selective loss of SH-SY5Y cells was 
clearly revealed. The number of remaining SH-SY5Y cells were significantly decreased 
following microglia activation (Ra 2 + LPS) compared to non-activated microglia (Ra 2) 
(p = 0.005) (Fig. 4). 
CTL Ra 2 LPS Ra 2+LPS
0
20
40
60
80
100
N
um
be
r o
f r
em
ai
ni
ng
 S
H
-S
Y5
Y 
ce
lls
 (%
)
 
Fig.4. The toxic effects of LPS-activated Ra 2 microglial cells on SH-SY5Y 
neuroblastoma cells in co-culture system. There was no SH-SY5Y 
neuroblastoma toxicity in absence of LPS or microglia, respectively. After 
exposure of LPS for 48 hrs, SH-SY5Y cells could be killed in the co-culture 
system. The number of GFP expressing SH-SY5Y cells were counted with 
GFP fluorescent cells in four random fields as described in Materials and 
Methods. The percentages of GFP expressing cells were calculated and the 
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values expressed were mean ± S.E. of 3 independent experiments. Statistic 
analysis: 1) P = 0.005 for Ra 2 + LPS as compared with Ra 2 cells; 2) P = 
0.935 for LPS as compared with CTL. 
The study of optimal condition of neuroblastoma-microglial co-culture  
a) Selection of cellular density: The human SH-SY5Y neuroblastoma cells were 
grown at a density allowing them to scatter evenly and differentiated separately in 
24-multiwell plates. A density of 9'000 cells/well was selected. The density of Ra 
2 microglial cells /well was varied to determine the effects of microglia density on 
the survival of SH-SY5Y cells. The final concentration of 0.1 µg/ml of LPS was 
added to activate the microglia. After incubation for 48 hrs, the number of 
remaining SH-SY5Y cells was determined and a significant relationship was seen 
between the decreasing of SH-SY5Y cells and the increasing number of Ra 2 
microglial cells. The optimal density of Ra 2 microglial cells (90'000/well) was 
selected (Fig. 5). 
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Fig. 5. The effects of Ra 2 microglial cell density in neuroblastoma-
microglial co-culture system. After 48 hrs of incubation, there was a dose-
dependent loss of SH-SY5Y cells with increasing number of Ra 2 microglial 
cells. The number of GFP expressing SH-SY5Y neuroblastoma cells were 
counted with GFP fluorescent cells in four random fields as described in 
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Materials and Methods. The percentages of GFP expressing cells were 
calculated and the values expressed were mean ± S.E. of 3 independent 
experiments. 
b) Selection of LPS concentration: With the human SH-SY5Y neuroblastoma cells at 
a density of 9'000/well and Ra 2 microglial cells at a density of 90'000/well in 24-
multiwell plates, the final concentration of LPS was varified. After 48 hrs 
stimulation, the number of remaining SH-SY5Y cells were counted and there was 
a significant dose-dependent decresing of SH-SY5Y cells with increasing 
concentration of LPS compared to control. An optimal condition of LPS (100 
ng/ml) in the co-culture was determined (Fig. 6). 
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Fig. 6. The effects of incremental LPS concentrations on neuroblastoma-
microglial co-culture system. After 48 hrs of incubation, there was a 
significantly dose-dependent loss of cells SH-SY5Y cells corresponding to 
increasing concentrations of LPS as compared with control. The number of 
GFP expressing SH-SY5Y cells were counted with GFP fluorescent cells in 
four random fields as described in Materials and Methods. The percentages 
of GFP expressing cells were calculated and the values expressed were mean 
± S.E. of 3 independent experiments. 
  Based on the above experiments, we presented here a simple, reproducible 
neuroblastoma-microglial co-culture system to demonstrate that LPS-activated microglia 
 42
  
were able to induce neuro-degeneration through the inflammatory mechanism in vitro. 
The cellular model was set up and the suitable conditions of the co-culture were: a) the 
density of human SH-SY5Y neuroblastoma cells: 9'000/well; b) the density of Ra 2 
microglial cells: 90'000/well; c) the final concentration of LPS: 0.1 µg/ml; d) incubating 
time: 48 hrs.  
The generation and characterization of GFP/APP-expressing neuronal cells  
  We generated APP-expressing SH-SY5Y cells through lentiviral transduction, of either 
APP-wt or APP-3m. The cells were also transduced with a GFP-expressing lentiviral 
vector to allow easy distinction of neuronal SH-5Y5Y cells from microglia. 
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Fig. 7. The time course of 4 types of cells suggested no marked difference of 
growth rate among them by counting method under the microscope. The 
number of human SH-SY5Y neuroblastoma cells was counted with DAPI 
staining, the rest of the other GFP expressing SH-SY5Y cells were counted 
with GFP fluorescent cells in four random fields as described in Materials 
and Methods. The values expressed were mean ± S.E. of 3 independent 
experiments. Statistic analysis: no significant differences (p > 0.05) 
To investigate whether expression of GFP/APP-wt or GFP/APP-3m was toxic to the SH-
SY5Y neuroblastoma cells, we examined cell growth and morphology. Growth curves of 
cells expressing GFP/APP-wt and GFP/APP-3m were identical to the wild-type of SH-
SY5Y neuroblastoma cells. The numbers of GFP-expressing SH-SY5Y neuroblastoma 
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cells by counting method under the microscope (SH-SY5Y neuroblastoma cells without 
expressing GFP were counted by DAPI staining) (Fig. 7). Similarly, Growth curves of  
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Fig. 8. The time course of 3 types of cells revealled no significant difference 
of growth rate among them by FACS counting method. 3 types of cells in 
density of 60'000 cells / well were seeded in 6-well plate for a duplicate in 2 
ml complete RPMI medium, respectively, then, the numbers of cell wes 
counted  as described in Materials and Methods. The values expressed were 
mean ± S.E. of 3 independent experiments. Statistic analysis: no significant 
differences (p > 0.05) 
cells expressing GFP/APP-wt, GFP/APP-3m were also identical to the control 
cells and the numbers of GFP-expressing SH-SY5Y neuroblastoma cells by 
FACS counting method. The expression of GFP/APP-wt (Fig. 11. left middle 
panel) or GFP/APP-3m (Fig. 11 left lower panel) did not alter cellular 
morphology.  
The toxic effects of hydrogen peroxide in the culture of control and GFP/APP-
expressing SH-SY5Y cells  
  In order to determine the natural reaction of control and APP-expressing neuroblastoma 
cells in the presence of H2O2,  we checked the toxic effects of H2O2 on control cells and 
GFP/APP-3m expressing neuroblastoma cells in culture, respectively. After 48 hrs, there 
was a marked dose-dependant loss of cells with increasing concentration of H2O2 (Fig. 9) 
as compared with control cells (without H2O2). The results demonstrated that both cell 
lines had the same sensitivity to H2O2.   
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Fig. 9. The toxic effects of hydrogen peroxide on control and GFP/APP-3m 
expressing SH-SY5Y cells in culture. The results demonstrated that the 
numbers of remaining SH-SY5Y cells were significantly decreased with 
increasing concentrations of H2O2 in both of cell lines. The number of GFP 
expressing SH-SY5Y cells were counted by FACSscan flow cytometer as 
described in Materials and Methods. The values expressed were mean ± 
S.E. of 3 independent experiments in the duplicates. 
Cell cycle analysis of control neuroblastoma cells and GFP/APP expressing 
neuroblastoma cells 
  In all experiments described above we did not find any difference among the wild-type 
of SH-SY5Y neuroblastoma cells, GFP-expressing SH-SY5Y neuroblastoma cells and 
GFP/APP expressing neuroblastoma cells. To further support above results, we 
performed cells cycle analysis. The data revealed that the percentages of the G1 phase 
were not significant different in 4 types of cells and the percentages of the S and G2/M 
phases were not greatly changed in 4 types of cells. These data demonstrated the 
expression of APP was not toxic to the neuroblastoma cells. 
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Fig 10. Cell cycle analysis of control neuroblastoma cells and GFP/APP 
expressing neuroblastoma cells. The data showed no significant differences 
of percentages of cells of G1, S and G2/M phases among the wild-type of SH-
SY5Y neuroblastoma cells, GFP-expressing SH-SY5Y neuroblastoma cells 
and GFP/APP expressing neuroblastoma cells by a FACSCalibur flow 
cytometer as described in Materials and Methods. The values expressed were 
mean ± S.E. of 3 independent experiments in the duplicates. 
The confirmation of APP-expressing SH-SY5Y neuroblastoma cells 
  APP expressing human SH-SY5Y neuroblastoma cells were examined by APP 
immunofluorescence. Positive immunostaining was seen in GFP/APP-wt (right middle 
panel) and GFP/APP-3m (right lower panel), which were the cytoplasmic domains of 
APP695 transduced in human SH-SY5Y neuroblastoma cells. Conversely, a negative 
immunostaining was detected in control cells (expressing only GFP human SH-SY5Y  
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Fig. 11. The immunofluorescence of APP showed the positive 
immunostaining in GFP/APP-wt (right middle panal) and GFP/APP-3m 
(right lower panal) transduced in human SH-SY5Y neuroblastoma cells, 
conversely,  immunostaining was absent in control cells (right upper panel). 
neuroblastoma cells) (right upper panel) (Fig. 11). The immunoblot analysis of 
transduced SH-SY5Y cells expressing GFP/APP demonstrated 2 bands with the expected 
molecular weight (MW) in APP-transduced cells (Fig. 12). One is mature APP (up), and 
the other is immature APP (down) (Tomita et al., 1999). Thus, at protein levels achieved 
by lentiviral expression, APP-wt and APP-3m did not lead to any detectable toxicity in 
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the human SH-SY5Y neuroblastoma cells and stable and homogeneous GFP/APP-wt and 
GFP/APP-3m expressing SH-SY5Y cells could be generated. 
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incubation for 48 hrs, the number of remaining SH-SY5Y cells decreased 
dose-dependently following the increase in number of Ra 2 microglial cells. 
The number of control cells was not changed with increasing the number of 
microglial cells, as LPS was absent. In addition, GFP/APP-3m was more 
sensitive to toxicity than GFP/APP-wt cells. The number of GFP expressing 
SH-SY5Y cells were counted with GFP fluorescent cells in four random fields 
as described in Materials and Methods. The percentages of GFP expressing 
cells were calculated and the values expressed were mean ±  S.E. of 3 
independent experiments.  
The toxic effect of Aβ-activated microglial cells on GFP/APP expressing SH-SY5Y 
cells in co-culture system 
  We co-cultured the GFP/APP-wt and GFP/APP-3m expressing SH-SY5Y cells with 
various numbers of Ra 2 microglial cells, in order to study whether Aβ could directly 
activate microglia and cause neuronal death. The results revealed that co-culture of 
increasing amounts of Ra 2 microglial cells with control cells did not affect the number 
of SH-SY5Y cells since LPS was not present. However, upon co-culture of increasing 
number of Ra 2 microglial cells with GFP/APP-wt and GFP/APP-3m expressing 
neuroblastoma cells, there was a marked decrease in the number of SH-SY5Y cells. The 
decrease in the neuronal cell number was an effect of microglial cells. There was a more 
pronounced effect on cells expressing APP-3m than their expressing APP-wt (Fig. 13). 
Subesquently, one condition of 3 types of cells above co-cultured with Ra 2 cells in the 
density of 9'000/well was selected to do the time course. Loss of neuroblastoma cells 
upon addition of microglia also occurred within a time frame of hours and was faster with 
GFP/APP-3m compared to GFP/APP-wt (Fig. 14). It suggested that Aβ could activate 
microglia to induce neuronal death. GFP/APP-3m expressing neuroblastoma cells had a 
more powerful toxicity than GFP/APP-wt expressing cells. GFP expressing cells were not 
toxic to human SH-SY5Y neuroblastoma cells.  
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Fig. 14. Time course of control and GFP/APP expressing SH-SY5Y cells with 
Ra 2 microglial cells in co-culture. The number of SH-SY5Y cells was 
markedly decreased on day 2 in GFP/APP-3m than in GFP/APP-wt cells. 
LPS was not present in control neuroblastoma-microglial co-culture. The 
number of neuroblastoma cells was gradually increasing with longer 
incubation. The number of GFP expressing SH-SY5Y cells were counted with 
GFP fluorescent cells in four random fields as described in Materials and 
Methods. The percentages of GFP expressing cells were calculated and the 
values expressed were mean ± S.E. of 3 independent experiments. 
NBT staining of co-culture of control and GFP/APP-expressing SH-SY5Y cells with 
Ra 2 microglial cells and inhibition of DPI in co-culture system 
  In our co-culture system, APP did not appear to be directly neurotoxic, but rather acted 
through microglia. The most likely scenario therefore would be an activation of microglia 
by APP-derived amyloidogenic peptides. We therefore performed NBT staining (a 
technique allowing to visualize cells that generate ROS) under co-culture conditions to 
detect activated microglia. No NBT-positive cells were detected upon co-culture of 
microglia with control cells (in the absence of LPS and Aβ) (Fig. 15A). However, most 
microglial cells became NBT positive within 2 hours of co-culture with APP-wt and 
APP-3m expressing neuroblastoma cells (Fig. 15B, and C). NBT-negative cells were 
observed when the NADPH oxidase inhibitor DPI (1 µM) was added to the co-culture of 
microglia and APP-3m expressing neurons (Fig. 15D). These results suggested that APP-
expressing neuroblastoma cells could activate microglia which may generate ROS.  
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Fig. 15. NBT staining of co-culture of control and GFP/APP-expressing SH-
SY5Y cells with Ra 2 microglial cells and inhibition of DPI in the co-culture 
after incubation of 2 hrs, revealed that : (A). No NBT-positive staining of co-
culture of control with Ra 2 microglial cells (10 X  magnification). (B) NBT-
positive staining of co-culture of GFP/APP-wt expressing SH-SY5Y cells with 
Ra 2 microglial cells (10 X  magnification). (C) NBT-positive staining of co-
culture of GFP/APP-3m expressing SH-SY5Y cells with Ra 2 microglial cells 
(10 X  magnification). (D) NBT-negative staining of co-culture of GFP/APP-
3m expressing SH-SY5Y cells with Ra 2 microglial cells by treatment with 
DPI (1 µM) (10 X  magnification).  
  To identify whether human SH-SY5Y neuroblastoma cells could generate ROS, 
neuroblastoma cells (5×104) were exposed to 1 mg/ml NBT solution and treated or not 
with 50 µM PMA as same method as described above. No NBT-positive staining were 
detected. It demonstrated that neuroblastoma cells could not generate ROS alone (data 
not shown). 
ROS scavengers and NADPH oxidase inhibitor prevents microglia-dependent death 
of APP-expressing neuroblastoma cells 
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  Activated microglia can kill human SH-SY5Y neuroblastoma cells. Release of ROS by 
microglia, as shown above in (Fig. 15), represents a potential underlying mechanism 
(Aisen and Davis, 1994; Akiyama et al., 2000; Bamberger and Landreth, 2002) In order 
to further substantiate the involvment of ROS participated in microglia-dependent 
neuronal killing, we employed ROS scavengers. Enzymatic ROS scavengers (SOD plus 
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Fig. 16. The effects of ROS scavengers on GFP/APP-3m expressing SH-SY5Y 
cells alone with Ra 2 microglial cell. There were no effects of ROS 
scavengers on GFP/APP-3m expressing SH-SY5Y cells in the culture (upper 
and left panel); The killing of GFP/APP-3m expressing neurons by microglia 
was partially and completely reversed by the inclusion of ROS scavengers 
andantioxidants in the co-culture of neuroblastoma-microglia (upper and 
right panel). The number of GFP expressing SH-SY5Y cells were counted 
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with GFP fluorescent cells in four random fields as described in Materials 
and Methods. The percentages of GFP expressing cells were calculated and 
the values expressed were mean ±  S.E. of 3 independent experiments. 
Statistic analysis: 1) p = 0.07 for Vit C&E as compared with Ra 2; 2) P= 
0.12 for SOD and Catalase as compared with Ra 2. The lower panel showed 
the result of the effects of ROS scavengers on GFP/APP-3m expressing SH-
SY5Y cells with Ra 2 microglial cell. The number of GFP expressing SH-
SY5Y cells were counted by FACSscan flow cytometer as described in 
Materials and Methods. The values expressed were mean ±  S.E. of 3 
independent experiments in the duplicates. Statistic analysis: 1) p = 0.0009 
for Vit C&E as compared with Ra 2; 2) P= 0.0007 for SOD and Catalase as 
compared with Ra 
catalase) and antioxidants (Vitamin E plus C) were used. Since ROS is known to be 
required for cell growth, we first investigated the effects of ROS scavengers on growth of 
neuroblastoma cells in the absence of microglia. No effects were observed (Fig. 16. upper 
and left panel). The killing of APP-expressing neurons by microglia were partially and 
completely reversed by the treatment by ROS scavengers and antioxidants in the 
expeirmental assay (Fig.16 upper and right panel, lower panel). Thus, a major component 
of neuronal killing in our system is due to ROS. 
  A likely source of ROS generation in our experimental system is the phagocyte NADPH 
oxidase which has been shown to be expressed in microglia, including in Ra 2 migrolial 
cell line used in this study (Vilhardt et al., 2002). 
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Fig 17. The effect of DPI in co-culture of control and GFP/APP-3m 
expressing SH-SY5Y cells with Ra 2 microglial cells. DPI was toxic to GFP 
expressing cells co-cultured with Ra 2 microglial cells in the absence of LPS, 
starting from concentrations around 5 µM. The results showed a biphasic 
curve In the submicromolar range, DPI in 1 µM completely rescued 
neuroblastoma cells from killing but a concentration over 5 µM was toxic to 
their cells. The number of GFP expressing SH-SY5Y cells were counted with 
GFP fluorescent cells in four random fields as described in Materials and 
Methods. The percentages of GFP expressing cells were calculated and the 
values expressed were mean ± S.E. of 3 independent experiments. 
We therefore investigated the effects of the NADPH oxidase inhibitor DPI in the co-
culture system. As DPI is a relatively non-specific inhibitor, it may, at least at higher 
concentrations, inhibit mitochondrial electron transport. We therefore first investigated its 
toxicity profile on neuroblastoma cells. As shown in (Fig. 17 left panel), DPI was toxic to 
neuroblastoma cells at concentrations at or above approximately 5 µM. Significant  
inhibition of the phagocyte NADPH oxidast also occurs in the submicromolar range. We 
proceeded to study the DPI effect on APP expressing neuroblastoma cells co-cultured 
with microglia. As shown in (Fig. 17 right panel), a biphasic curve can be observed. DPI 
was protective in the submicromolar rangeg at 1 µM. It was able to completely rescue 
neuroblastoma cells from killing. At concentrations over 5 µM, DPI became toxic to 
human neuroblastoma cells.  
The toxic effects of Aβ-activated PLB cells on control and GFP/APP-3m expressing 
SH-SY5Y cells in co-culture system 
  In order to determine whether Aβ could directly activate PLB cells and result in 
neuronal death, we co-cultured control cells or GFP/APP-3m expressing SH-SY5Y cells 
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Fig 18 The toxic effects of Aβ-activated PLB cells on control and GFP/APP-
3m expressing SH-SY5Y cells after an incubation period of 2 days, 
demonstrated no significant change of numbers of control cells with PLB-wt 
and PLB X-CGD cells (left panel). The numbers of remaining SH-SY5Y cells 
were the significant dose-dependent loss of viable cells following increasing 
number of PLB-wt compared to controls. Conversely, the number of SH-SY5Y 
cells was not obviously different with increasing number of PLB X-CGD cells 
as compared to the controls. The number of GFP expressing SH-SY5Y cells 
were counted with GFP fluorescent cells in four random fields as described 
in Materials and Methods. The percentages of GFP expressing cells were 
calculated and the values expressed were mean ± S.E. of 3 independent 
experiments. 
with either PLB-985-wt or PLB-985 X-CGD cells. After 48 hrs incubation, the number of 
control cells were unaltered, because of  the absence of LPS and Aβ in co-culture system 
(Fig. 18. left panel). In contrast, the number of GFP/APP-3m expressing SH-SY5Y cells 
was significantly decreased with increasing number of PLB-985-wt, and not obviously 
different with increasing number of PLB-985 X-CGD cells (Fig. 18. right panel). The 
results showed that Aβ could activate PLB-985-wt cells, which could generate ROS 
through the pathway of NADPH oxidase and kill human SH-SY5Y neuroblastoma cells. 
Conversely, PLB-985 X-CGD, which lack NADPH oxidase, could not be activated by Aβ 
 55
  
to produce ROS. Hence the conclusion of the hypothesis that ROS released by microglia 
was generated through the NADPH oxidase (Nox 2) pathway expressed in microglia.  
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Discussion 
 
  The complexity of microglia-neuron interactions makes it difficult to perform in situ 
experiments and to interpret the results. In vitro, toxic or protective effects are not always 
easily attributed to a specific cell type and differences in isolation and culture methods 
might lead to conflicting results. An appropriate model using established cell lines would 
offer the possibility to elucidate different aspects of neuroinflammation in a controlled 
environment before validating the results in various in vivo/in situ models. 
  The objective of this project is to investigate the relationship between APP, microglia 
cells and neuronal toxicity. Here, a co-culture system was used in which human neuronal 
cells and microglia are grown in the same dish, allowing more complex interactions 
between microglia and neurons than can be achieved by other culture systems such as 
microglia conditioned medium. It also allows not only short lived species released from 
microglia to exert an effect on the neurons, but also APP to act on microglia. The use of 
immortalized cell lines in this co-culture system has advantages over the use of primary 
cell cultures. The toxic or protective effects of cells are always easily attributed to 
expected results. This cell line in co-culture system also allowed establishment of stable 
cell lines by gene manipulation. 
  In our study, we first co-cultured a GFP-expressing human SH-SY5Y neuroblastoma 
cell with the Ra 2 microglia cells in order to confirm that microglia activated by LPS 
directly kill the neuronal cells. The findings indicated that microglial activation could 
cause neuronal cell death in correlation with both the number of microglia and the dose 
of LPS. We found that microglial activation could also result in apoptosis and neuro-
degeneration. These results are consistent with our previous studies (Cartier et al., 2003; 
Vilhardt et al., 2002).  
  APP was identified as a causative factor in the pathogenesis of AD (Braak et al., 1998; 
Nagy et al., 1998). Several mutations of APP and other AD-related genes have been 
found in familial AD. It has been reported that these mutations contribute to the 
pathogenesis of familial AD (Bamberger and Landreth, 2002; Nagy et al., 1998). Though 
familial AD represents only a small minority of AD cases, the majority of AD cases are of 
the sporadic types, who do not carry the mutation. Mutations associated AD are important 
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for understanding the mechanism of the progressive cerebral Aβ deposition that occurs in 
all cases of AD. We used lentiviral transduction, as previously described (Zufferey et al., 
1997), to generate a stable human SH-SY5Y neuroblastoma cell line expressing by APP. 
As expected, APP was detected by immunofluorescence and Western blotting (Tomita et 
al., 1999) in neuroblastoma cells. Expression of APP-wt and APP-3m did not lead to any 
detectable toxicity in the human SH-SY5Y neuroblastoma cells. Thus, our system does 
not suggest a direct neurotoxicity of APP or pathogenic APP mutants. However an 
alternative explanation is that the density of APP-expressing SH-SY5Y cells was diluted 
too much and that the incubation time of 2 days was too short in our experimental assay. 
Thus, our results do not exclude that Aβ itself may exert direct neurotoxic effects and 
may promote oxidative damage to the neuron in several ways, including lipid 
peroxidation, protein oxidation, and formation of ROS in AD brain tissues. (Butterfield et 
al., 2002). The morphology of APP-expressing SH-SY5Y cells were not markedly 
changed as compared to control cells. Both control and APP-expressing neuroblastoma 
cells had similar growth rate and sensitivity to H2O2. A clinical feature of AD is an 
insidious onset with a gradual progression (Chronic inflammation in pathogenesis of AD) 
and its typical pathological characteristic is the presence of SP. Taking these facts into 
account, we presented a novel, simple, reproducible and AD type cellular in vitro model. 
  Activated microglia around the Aβ is a common pathologic finding in AD-affected 
brains. The microglial activation in the pathogenesis of AD was initially postulated to 
play an important role. Several studies have suggested that activated microglia could 
release inflammatory mediators to induce neuro-degeneration (Apoptosis) through 
inflammatory mechanism. ROS is one of the most potential attributors to cause neuro-
degeneration (Aisen and Davis, 1994; Akiyama et al., 2000; Bamberger and Landreth, 
2002; Streit, 2004). To test this hypothesis, an inflammation mediated cellular model of 
AD was established, using co-culture of APP-expressing SH-SY5Y cells with Ra 2 
microglial cells, in which the cytotoxicity of the neuronal cells clearly occurred. Our data 
demonstrated that the expression of APP led to the activation of microglia cells and APP-
3m had a more powerful toxicity than APP-wt. In addition, NBT staining (directly 
visualizing Ra 2 cells that generated ROS) indicated that ROS were produced in 
microglia cultured with APP-expressing neuroblastoma cells, but not in microglia 
 58
  
cultured with control cells. These findings showed that APP could directly activate 
microglia to produce O2  and ROS, resulting in neuronal cells death. Further more, the 
ROS scavenging enzymes, (SOD and catalase) and the antioxidants, (vitamin E and 
vitamin C), were able to reduce the neuronal toxicity in the co-culture of APP-expressing 
SH-SY5Y cells with Ra 2 microglia cells. In addition, DPI is a related non-specific potent 
and reversible inhibitor of NADPH oxidase. At high concentrations, DPI was directly 
toxic, but at lower concentrations, including 1 µM, it was sufficient to inhibit microglial 
ROS production. Thus, DPI was able to prevent neuronal toxicity in the co-culture 
system. The substantial evidences suggested that neuronal APP expression could activate 
microglia to release ROS, which play a critical role in regulating apoptosis. Furthermore, 
the inhibition of NADPH oxidase by DPI was able to prevent the production of ROS 
indicating that this enzyme is responsible for the generation of ROS in microglia 
activated by APP. These results are consistent with published studies (Akiyama et al., 
2000; Bamberger and Landreth, 2002; Streit, 2004). 
  An important source of ROS common to all cells is the mitochondrial electron transport 
system (Babior, 1999; Quillet-Mary et al., 1997; Wang et al., 1996). It catalyzes the 
transfer of electrons from the substrate NADPH to O2, via intermediate FAD and heme 
prosthetic groups, to produce O2 . The superoxide generated by the phagocyte NADPH 
oxidase forms the basic compound of ROS, which in turn leads to the production of 
secondary derivatives such as OH  and H2O2. In the present study, we employed the co-
culture of control cells or APP-expressing SH-SY5Y cells with 2 types of PLB cells to 
further investigate the role of the phagocyte NADPH oxidase in the production of ROS. 
Two human leukemia cells lines X-CGD and PLB-985 were used. The former is derived 
from the latter by inactivation of an essential component, gp91-phox (Chanock et al., 
1994; Morel et al., 1991; Roos et al., 1996). Expression of APP in human SH SY5Y cells 
led to activation of PLB-985 cells in the co-culture and resulted in neuronal cell death. 
The cells with the inactive gp91-phox enzyme did not cause neuronal toxicity. Thus, 
these findings clearly proposed that APP expression in neuroblastoma cells could cause 
activation of microglia, which in turn produce ROS through the pathway of NADPH 
oxidase (Nox 2) which is expressed in Ra 2 microglial cells. The release of the ROS 
resulted in neuronal cell death (apoptosis).  
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